Investigations of the Telomerase Template Antagonist GRN163L and Implications for Augmenting Breast Cancer Therapy by Goldblatt, Erin M.
 
 
 
 
INVESTIGATIONS OF THE TELOMERASE TEMPLATE ANTAGONIST GRN163L 
AND IMPLICATIONS FOR AUGMENTING BREAST CANCER THERAPY 
 
 
 
 
 
Erin M. Goldblatt 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Medical and Molecular Genetics,  
Indiana University 
 
 
December 2008 
 
 
 ii
Accepted by the Faculty of Indiana University, in partial  
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
 
 
 
 
_____________________________ 
Brittney-Shea Herbert, Ph.D., Chair 
 
 
 
 
_____________________________ 
Marc S. Mendonca, Ph.D. 
 
Doctoral Committee 
 
 
_____________________________ 
Kenneth E. White, Ph.D. 
 
 
October 16, 2008 
 
_____________________________ 
Meei-Huey Jeng, Ph.D. 
 
 
 
 
_____________________________ 
George W. Sledge Jr., M.D. 
 
 
 
 
 
 
 
 iii
ACKNOWLEDGEMENTS 
  
 
I would first and foremost like to thank Dr. Brittney-Shea Herbert for being my 
mentor for the past four years, and for all of the support and motivation she has provided. 
Without her ideas, knowledge, and understanding I would not be where I am today. Dr. 
Herbert has been more than a scientific mentor to me, and I greatly appreciate the life 
advice she has given me as well. Her passion has inspired me, and I will never forget the 
time I have spent working with her.  
I would like to sincerely thank the members of my research committee, Dr. 
Mendonca, Dr. White, Dr. Jeng, and Dr. Sledge, for all of their guidance and assistance. 
The insights and ideas they have provided have helped shape my research, and their 
support invaluable. I could not have asked for a better committee to teach me, guide me, 
and encourage me. My fellow graduate students also have my gratitude for the friendship 
and understanding they have given me throughout our time at Indiana University. This 
endeavor would not have been possible without their support. I thank my coworkers, both 
past and present, for all of the help they have given me, and more importantly, for their 
friendship. Thank you also to Jeremy Farrow for his help with graphics used in this 
dissertation. 
Finally, I would like to thank my friends and family for standing by me through 
my graduate school career. They are all amazing people and I truly cherish each and 
every one. Without them, I would not be who I am today. Their love and support means 
the world to me, and I thank them for being by my side during this journey.  
 iv
ABSTRACT 
Erin M. Goldblatt 
 
INVESTIGATIONS OF THE TELOMERASE TEMPLATE ANTAGONIST GRN163L AND 
IMPLICATIONS FOR AUGMENTING BREAST CANCER THERAPY 
 
Breast cancer is the second most common cancer among women in the US after 
skin cancer. While early detection and improved therapy has led to an overall decline in 
breast cancer mortality, metastatic disease remains largely incurable, indicating a need 
for improved therapeutic options for patients. Telomeres are repetitive (TTAGGG)n DNA 
sequences found at the end of chromosomes that protect the ends from recombination, 
end to end fusions, and recognition as damaged DNA. The enzyme telomerase acts to 
stabilize short telomeres, preventing apoptosis or senescence due to genomic instability. 
Telomerase is active in 85-90% of cancers, and inactive in most normal cells, making 
telomerase an attractive target for cancer therapy. Use of the telomerase-specific, 
lipidated oligonucleotide GRN163L can antagonize telomerase activity and telomere 
maintenance in cancer cells by preventing telomerase from binding to telomeres. 
GRN163L has been shown by our laboratory to inhibit breast cancer cell growth and 
metastasis in animal models. However, the mechanisms of cancer cell growth and 
metastatic inhibition via GRN163L are not completely understood. The overall goal of 
this research project was to further elucidate the role of telomerase in breast cancer cell 
survival by: 1) determining the effects of combining telomere dysfunction induced by 
GRN163L with a DNA damage inducer (irradiation); 2) elucidating the mechanisms 
underlying the cellular response to GRN163L and the effect of combination therapy with 
 v
the mitotic inhibitor paclitaxel; and 3) testing the hypothesis that a telomerase inhibitor 
can augment the effects of trastuzumab in breast cancer cells with HER2 amplification. 
Results support the central hypothesis that the telomere dysfunction, structural and 
proliferative changes in breast cancer cells induced by GRN163L can synergize with 
irradiation, paclitaxel, and trastuzumab to inhibit the tumorigenicity of breast cancer cells 
both in vitro and in vivo. Furthermore, GRN163L can restore sensitivity of 
therapeutically resistant breast cancer cells to trastuzumab. These results provide insight 
into the role of telomerase in cancer cell growth. Additionally, implications of this 
research support GRN163L as an important part of therapeutic regimens for primary 
tumors, recurrence, and metastatic disease. 
 
Brittney-Shea Herbert, Ph.D., Chair 
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Chapter One 
Introduction and Literature Review 
 
Breast cancer is the second most common cancer among women in the US after 
skin cancer. While early detection and improved therapy has led to an overall decline in 
breast cancer mortality, metastatic disease remains largely incurable, indicating a need 
for improved therapeutic options for patients. Breast cancer patients are often treated with 
therapeutic regimens that can be cytotoxic and result in harmful secondary effects. 
Treatment methods include the use of radiation, chemotherapy, and molecular targeted 
therapy; however resistance often develops quickly in more advanced breast cancer, 
resulting in tumor recurrence and/or metastatic disease (Polyak 2007). There are six 
major hallmarks of cancer, with limitless replicative potential (cellular immortality) being 
one of these six acquired capabilities (Hanahan and Weinberg 2000). Cells are believed 
to have a counting mechanism that regulates cellular lifespan, which is defined by 
repetitive DNA sequences called telomeres found at the end of chromosomes. Telomeres 
shorten with each round of cell division due to the end replication problem (Hanahan and 
Weinberg 2000). In cancer, however, telomere length is maintained, resulting in the 
immortal phenotype. The research presented within this dissertation will focus on 
targeting this hallmark in breast cancer cells and its implications in breast cancer therapy 
in combination with three other conventional cancer therapies. Using these combination 
therapies is likely to improve treatment regimens, as targeting multiple pathways 
involved in cancer progression is likely to increase patient survival over single drug 
therapy.  
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Telomeres and their role in replicative cellular aging and cancer 
Telomeres are specialized structures at the end of chromosomes consisting of 5-
12 kb of repeated (TTAGGG)n sequences in humans and are essential for cell survival 
(Figure 1.1). Telomeres act to protect the ends of chromosomes from recombination, end-
to-end fusions, and recognition as damaged DNA. Telomeres contain a short, single 
stranded 3'-overhang of approximately 3 kb that forms a loop structure (t-loop) by 
inserting into double stranded telomeric DNA. This loop structure protects the 3' end of 
the DNA from degradation or unregulated elongation by telomerase (discussed below). 
Telomeres are lost from the lagging strand of DNA with each cell cycle in normal cells 
and shorten until one or more become critically short, or dysfunctional, triggering a cell 
growth arrest, termed replicative senescence (Figure 1.1; Kim et al. 2002, Blackburn 
2001, Cong et al. 2002, Hahn 2003).   
Telomere structure and stability is maintained through many telomere associated 
proteins (Hahn 2003, Kim et al. 2002). Two structurally related DNA binding proteins, 
TRF1 and TRF2, bind double stranded telomeric DNA and play an important role in 
maintaining telomere length. Overexpression of wild-type TRF1 resulted in telomere 
shortening, whereas mutant TRF1 induces telomere elongation (van Steensel and de 
Lange 1997, van Steensel et al. 1998). TRF2 has been shown to assist in the formation of 
the t-loop and maintain genomic stability. Expression of dominant negative TRF2 has 
been shown to result in end-to-end chromosome fusions and senescence (Hahn 2003, 
Bryan and Cech 1999). A third DNA binding protein, POT1, binds to single stranded 
telomeric DNA and helps maintain the t-loop structure (Kim et al. 2002, Hahn 2003, 
Bryan and Cech 1999). Several telomere associate proteins have also been shown to be a  
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Figure 1.1. Telomeres act as protective caps at the end of chromosomes. (A) 
Telomeres are located at the ends of chromosomes. In this fluorescence in situ 
hybridization (FISH) figure, the chromosomes (DNA) are stained with DAPI (blue). 
Telomeres are depicted as red signals at the ends of each chromosome arm. Figure 
courtesy of the Herbert laboratory (unpublished data). (B) Telomeres shorten during each 
round of cell division. In cells with telomerase activity, telomere length is maintained, 
providing cells with the ability to proliferate indefinitely. 
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part of the DNA damage response pathway (Hahn 2003, Kim et al. 2002). This includes 
two DNA repair enzymes, TANK1 and TANK2, which seem to help regulate the activity 
of TRF1. The Ku complex also localizes to the telomeres and is involved in the 
processing of the single-strand overhangs, as well as protecting the telomere from 
degradation and recombination (Kim et al. 2002, Hahn 2003, Bryan and Cech 1999).   
DNA is constantly bombarded by exogenous and endogenous damaging agents 
that can induce mutations, genomic instability, and ultimately lead to cancer 
development. In most cases, however, cells become senescent due to telomere 
dysfunction before they acquire enough mutations to become cancerous, indicating that 
growth arrest induced by short telomeres may be an intrinsic anti-cancer mechanism 
(Shay et al. 2001, Hahn 2003, Kim et al. 2002). Cell growth arrest and cell death are seen 
in response to dysfunctional telomeres, although this may be at least partially dependent 
on functional p53 and Rb pathways. In cells with mutant Rb, but functional p53, cell 
death is more likely to occur in response to critically short telomeres. If both pathways 
are inactive, however, cells can bypass senescence and proliferate until telomeres reach 
critically short lengths, at which time cells undergo crisis (Kim et al. 2002). Most cells 
will die at this stage; however, a few cells will be able to escape crisis and continue to 
proliferate uncontrollably. The ability of cells to escape this crisis stage is thought to be 
one of the major hallmarks of cancer development, leading to evasion of telomere-based 
growth limitations (Shay and Wright 2002, Hanahan and Weinberg 2000). Importantly 
for cancer development, cells that escape crisis are highly susceptible to end to end 
fusions, breakage fusion bridge (BFB) cycles, and genomic instability due to telomere 
5 
dysfunction, increasing the chances of activation of telomere maintenance pathways (i.e., 
telomerase reactivation). 
 
Telomerase and cancer 
One critical hallmark of cancer is the ability of cells to proliferate indefinitely or 
bypass senescence (Hanahan and Weinberg 2000). The most common method for cells to 
escape replicative senescence is the reactivation of telomerase to maintain telomeres. 
Human telomerase is a ribonucleoprotein complex consisting of a catalytic reverse 
transcriptase component (hTERT) and an RNA template (hTR) that act to elongate 
existing telomeres by synthesizing de novo telomeric repeats onto the 3'-overhang end 
using the hTR template as a template for extension (Figures 1.2 and 1.3; Shay et al. 2001, 
Hahn 2003, McEachern et al. 2000). In humans, telomerase is expressed during 
embryonic development but is repressed in most adult tissues. In cancer development, 
however, telomerase activity is reactivated through unknown mechanisms (Cong et al. 
2002, McEachern et al. 2000, Kim et al. 2002). hTERT alone has been shown to be 
sufficient for cellular immortalization and allowing transformed cells to escape from 
crisis (Bodnar et al. 1998). 
Importantly, telomerase reactivation can cooperate with the aberrant expression of 
oncogenes and tumor suppressor genes to induce neoplastic transformation of normal 
human epithelial cells (Cong et al. 2002). Interestingly, telomerase-proficient stem cells 
still exhibit telomere shortening, indicating that at least in some cases, telomerase activity 
is not sufficient to prevent telomere erosion and senescence (Kim et al. 2002). Despite the 
high percentage of cancer cells expressing telomerase activity, a small minority of
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Figure 1.2. The telomerase complex. The telomerase complex consists of a catalytic 
protein subunit (hTERT) and an RNA template component (hTR). The intrinsic RNA 
template region recognizes and binds to telomeric DNA sequences (consisting of 
TTAGGG repeats, approximately 5-12 kb in length in humans) to maintain telomere 
length.  
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Figure 1.3. Telomerase maintains telomere length. The RNA template region of 
telomerase (hTR) recognizes and binds to telomeric DNA and extends the 3' end of the 
parental DNA strand via the catalytic activity of hTERT. DNA polymerase can then act 
on the 5' end of the lagging strand to maintain telomere integrity. Adapted from Alberts 
et al. Molecular Biology of the Cell, 2002. 
8 
cells maintain stable telomeres without the expression of hTERT or telomerase. This 
telomere stabilization is achieved through a second form of telomere maintenance termed 
alternative lengthening of telomeres (ALT), which is dependent on recombination. ALT-
positive cells are mainly found in sarcomas and in vitro SV40-transformed fibroblasts. 
Interestingly, telomere maintenance through ALT and telomerase reactivation has been 
proposed to coexist, indicating that these mechanisms are not mutually exclusive (Hahn 
2003). 
 The telomerase RNA component, hTR, is a member of a class of small nucleolar 
RNA molecules and is universally expressed in all tissues. Despite differences in the 
primary sequence of the hTR gene between species, the secondary structure is highly 
conserved, indicating the importance of the RNA structure in telomerase function (Cong 
et al. 2002). siRNAs targeting hTR have been shown to decrease telomerase activity and 
inhibit xenograft tumor formation without the shortening of the overall telomere 
population (Zimmermann and Martens 2007, Shammas et al. 2005). Additionally, 
depletion of wild-type hTR using a mutated template hTR (mt-hTR) results in the 
synthesis and incorporation of “mutant” telomeric DNA, which can subsequently affect 
the binding of protective telomere-associated proteins and telomere structure (Feng et al. 
1995, Goldkorn and Blackburn 2006, Cerone et al. 2006b). Mt-hTR has also been shown 
to decrease cell viability and increase apoptosis independently of initial telomere length, 
as well as inhibit tumorigenesis in mice and increase the sensitivity of cancer cells to 
chemotherapeutic agents (Saretzki 2003, Kim et al. 2001, Cerone et al. 2006b, Goldkorn 
and Blackburn 2006). The catalytic subunit of telomerase, hTERT, is only found in cells 
that express telomerase activity, indicating that hTERT is the rate limiting component of 
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the telomerase enzyme (Cong et al. 2002, Hahn 2003). As with hTR, the sequence of 
hTERT is highly conserved between species. To support the importance of hTERT in 
telomere maintenance, it has been shown that introducing exogenous hTERT into 
primary cells results in the induction of telomere maintenance and escape from 
senescence. Conversely, introducing a single amino acid mutation into the primary 
hTERT sequence leads to telomere shortening and senescence (Cong et al. 2002).  
Telomerase activity can be detected in 85-90% of human tumors, but not in most 
normal tissues, making telomerase an attractive target for cancer therapy (Kim et al. 
1994). A correlation between increasing telomerase activity from early to late stage 
tumors has been observed (Kim et al. 2001, Watanabe et al. 2002). Furthermore, telomere 
lengths in ductal carcinoma in situ (DCIS) and invasive breast cancer are shorter than in 
normal surrounding tissue (Meeker et al. 2004). Maintenance of telomeres by telomerase 
is essential for the survival of tumor growth and for metastasis, allowing for stabilization 
of genomic instability triggered by short telomeres (Bryan and Cech 1999, Herbert et al. 
2001, Meeker et al. 2004). 
 
 Importance of telomere maintenance and telomerase in cell survival 
Telomere dysfunction is associated with diseases of aging, poor wound healing, 
and vascular disease (Kim et al. 2002). In addition to its role in cancer, telomerase plays a 
role in other human diseases as well. Mutations in either hTR or hTERT are associated 
with several diseases, including dyskeratosis congenita, bone marrow failure, and 
idiopathic pulmonary fibrosis (Garcia et al. 2007). Mutations in genes encoding hTERT 
and hTR alter the level of telomerase activity and inhibit the proliferative capacity of 
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cells in a range of tissues, as sufficient telomerase activity in somatic cells is critical for 
human health and viability (Collins and Mitchell 2002). Collectively, the involvement of 
telomerase in the development of these diseases indicates that telomerase may be far 
more important in regulating human growth and development than has previously been 
known.  
As stated above, mutations in hTR and hTERT, or in the associated protein 
dyskerin, result in aplastic anemia, premature organ failure, and dyskeratosis congenita 
(DKC), which further implicates the essential role of telomerase in cell and organismal 
survival (Collins and Mitchell 2002, Hahn 2003). In normal cells, the protein dyskerin is 
a nuclear protein that is responsible for early steps in RNA regulation and is involved in 
the processing of hTR. Loss of association between dyskerin and telomerase leads to the 
loss of normal telomere maintenance (Hahn 2003). A number of different mutations in 
both hTR and TERT have been found in patients with bone marrow failure syndromes, 
leading to a reduction in telomere length. The lack of telomerase activity and short 
telomeres in bone marrow cells may be a marker of progenitor cell depletion in bone 
marrow failure syndromes. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal 
lung disease characterized by lung scarring and abnormal lung tissue function. The 
mutations resulting in IPF are different from those found in DKC, although DKC patients 
do often present with pulmonary fibrosis. While the mutations between these three 
conditions differ, there are underlying similarities between DKC, IPF, and bone marrow 
failure syndromes (Garcia et al. 2007). 
 The use of mouse models has become an informative method for understanding 
how telomeres and telomerase function in mammals. There are, however, significant 
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differences in telomere biology between mouse and human. Laboratory mouse telomeres 
are substantially longer than human telomeres, suggesting that the effects of telomerase 
inhibition may take longer than would be seen in a human. Additionally, telomerase is 
poorly repressed in mice, with expression found in most tissues (Hahn 2003). These 
findings led to the generation of mouse models that lack the RNA component of 
telomerase (mTR), which provided the in vivo proof that loss of one of the telomerase 
complex components resulted in lack of telomerase activity and telomere shortening 
(Blasco et al. 1997). Due to the length of murine telomeres, however, the mTR knockout 
mice did not demonstrate phenotypes associated with telomerase/telomere dysfunction 
until the sixth generation, when telomeres had significantly shortened. At this point, 
knockout mice displayed defects in normal cellular function in highly proliferative 
tissues, indicating that telomere shortening limits the proliferation of cells in vivo. When 
the mTR knockout was bred with mice harboring mutations in cell cycle checkpoint 
genes or with mice that were exposed to known chemical carcinogens, mice were less 
prone to develop cancer (Blasco et al. 1997, Hahn 2003). However, when combined with 
mutations in tumor suppressor genes such as p53, an increase in cancer rates was 
observed particularly epithelial cancers. The increase in cancer incidence was associated 
with an increase in genomic instability in these tumors (Hahn 2003). Taken together, this 
research provided insight into the importance of telomere and telomerase function in 
human disease, particularly epithelial cancers such as breast cancer.   
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Breast cancer 
Breast cancer is the most frequently diagnosed cancer in women, with an 
estimated 180-200,000 new cases expected to be diagnosed in 2008 in the United States, 
and one million cases expected worldwide. About 40,000 women and 450 men will die 
from the disease in 2008. A large number of risk factors are associated with the 
development of breast cancer, including race, age at menses or menopause, age at first 
pregnancy, the use of birth control pills, and lifestyle choices (alcohol consumption, 
exercise, and diet). Women over the age of 55 or with close blood relatives with breast 
cancer have a higher risk of developing the disease themselves. Genetics also play a role 
in breast cancer risk, with approximately 5-10% of breast cancers thought to be due to 
inherited genetic mutations. Breast cancer cannot be prevented, although limiting the 
exposure to known risk factors may lower the chance of developing cancer (American 
Cancer Society, www.cancer.org). The high incidence of breast cancer emphasizes the 
lack of complete understanding about the cause of this disease and how to successfully 
prevent and cure development and recurrence (Hinestrosa et al. 2007). 
The development of breast cancer involves progression through defined 
pathological and clinical stages, starting with ductal hyperproliferation, followed by 
subsequent evolution towards in situ and invasive carcinomas, and finally into metastatic 
disease (Polyak 2007). The biology of breast cancer development, however, remains 
poorly understood. There are many prognostic factors that indicate potential disease 
outcomes, including presence of metastases, histologic grade, expression of steroid and 
growth factor receptors, expression of oncogenes, and suppression of tumor suppressor 
genes. However, these factors alone only provide limited information about the biology 
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of the disease. The heterogeneity of breast tumors and the large number of factors 
involved in the development of tumors emphasizes the importance of conjointly studying 
multiple genetic alterations together. This has led to the classification of distinct subtypes 
based upon gene signatures. There are currently five distinct subtypes of breast cancer 
based on gene expression arrays: basal-like, luminal A, luminal B, HER2+, and normal 
breast-like. Understanding these differences is vital to developing targeted cancer-
preventative and -therapeutic interventions (Sørlie et al. 2001, Sørlie et al. 2005, Polyak 
2007). The research presented within this dissertation will focus upon the two subtypes 
with the shortest disease-free and overall survival times, the basal-like and HER2+ 
subtypes. 
Basal-like breast cancers are often described as “triple negative” due to lack 
expression of estrogen receptor (ER), the progesterone receptor (PR), and amplification 
of the HER2 receptor. Because of this, patients with basal-like breast cancer face a poor 
prognosis and are not responsive to therapies targeting these receptors. In addition, basal-
like cancers often have an elevated frequency of p53 mutations, high levels of genomic 
instability, and are highly invasive (Shakya et al. 2008). HER2 (human epidermal growth 
factor receptor 2) is a member of the ErbB/EGFR family of transmembrane receptor 
tyrosine kinases that plays a role in tumor cell growth, invasion, and metastasis (Slamon 
et al. 2001, Ross et al. 2004, Hudis 2007). HER2 amplification is found in approximately 
10-20% of breast cancers and is associated with a more aggressive disease, greater 
likelihood of recurrence, poorer prognosis and decreased survival compared to women 
with HER2-negative breast cancer (Ross et al. 2004, Menendez et al. 2005, Sledge 2004). 
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In addition, HER2 overexpression is associated with resistance to chemo- and endocrine 
therapies (Menendez et al. 2005, Burstein 2005, Tan et al. 1997). 
 
Cancer therapy: current approaches and new advances 
Over the past twenty to thirty years, there have been significant advances in 
diagnosing and treating breast cancer. Early diagnosis remains one of the best factors for 
successfully treating breast cancer. Cancer prevention has also come under investigation, 
with much research aimed at determining who is at risk for cancer and how to prevent it 
from developing in these individuals. Approximately 20% of women with a history of 
early breast cancer will develop metastatic disease (Stevanovic et al. 2006) and metastatic 
tumors are responsible for approximately 90-100% of cancer related deaths. These 
numbers highlight the importance of research into understanding tumor progression and 
recurrence so that advanced breast cancer can be treated successfully. This understanding 
includes determining gene signatures of breast cancer subtypes and recognizing the 
response of each subtype to a certain type of therapy. Knowing how an individual tumor 
will respond to treatment will lead to the development of individualized therapeutic 
regimens, thus maximizing results while minimizing exposure time to toxic therapeutics.  
One of the most important areas of research is in understanding the response to therapy, 
and how resistance develops in a large number of cancers, in order to help prevent or 
overcome resistance (Polyak 2007). 
Most women with breast cancer will undergo surgery to remove as much of the 
cancer as possible. Early stage breast cancer is largely curable. Typically, after surgical 
removal of the tumor mass, breast cancer patients are treated with radiation to induce 
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lethal DNA damage and cell death in remaining cancer cells. Additional therapy involves 
the use of chemotherapeutic drugs that are highly toxic and lack selectivity. Despite high 
cure rates in early stage disease, resistance to therapy often develops quickly in advanced 
disease. Current therapies are aimed to prolong survival, control symptoms, and maintain 
quality of life (Orlando et al. 2007, Barni and Mandalà 2005). Metastatic breast cancer is 
generally incurable with a low number of patients achieving long-term survival after 
standard chemotherapy (Welch et al. 2000, Stevanovic et al. 2006). Although there are a 
large number of agents available for the treatment of metastatic disease, overall survival 
has changed little during the last half century. The research presented herein will focus on 
three different types of cancer therapy; ionizing radiation, chemotherapy (specifically 
paclitaxel, a microtubule stabilizing drug), and targeted therapy using trastuzumab, a 
monoclonal antibody against the HER2 receptor. A more detailed introduction to each 
method of treatment will be given in the following chapters. 
 
Ionizing radiation 
Ionizing radiation (IR) is an important cancer therapy that utilizes high-energy 
rays to kill cancer cells by inducing lethal DNA damage and double-stranded breaks 
(Bernier et al. 2004). IR is often used in conjunction with either surgery or chemotherapy 
to shrink a tumor or inhibit re-growth. In early-stage breast cancer, radiation significantly 
reduces the risk of local recurrences (Haffty et al. 2006). In cases of invasive disease, 
adjuvant chemotherapy precedes IR, as these two therapeutic techniques are not generally 
used together due to added toxicities. Studies in mammals and yeast have shown that 
mutations in genes responsible for DNA double-strand break repair resulted in increased 
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IR sensitivity (Goytisolo et al. 2000). Although radiation therapy is well tolerated, several 
adverse effects have been reported. These effects can include secondary cancers, skeletal 
complications, radiation-induced heart disease, and lung disease (Hirbe et al. 2006, 
Munshi 2007). There are two primary ways in which radiation therapy can be given: 
external radiation, in which a tumor is subjected to a beam of radiation, or by placing 
radioactive pellets into the normal tissue next to the cancer (American Cancer Society, 
www.cancer.org). Internal radiation therapy is also known as brachytherapy, which 
allows for delivery of a high dose of radiation to a small area. It is useful in cases that 
need a high dose of radiation or a dose that would be more than the normal tissues could 
stand if given externally. There is ongoing research into methods to deliver radiation 
more effectively, limiting the toxicity to normal tissues surrounding the tumor. This 
includes research into agents that sensitize cancer cells to radiation, or protect normal 
cells from damage induced by radiation (American Cancer Society, www.cancer.org). 
 
Chemotherapy 
Chemotherapy is an important treatment option for many cancers. Chemotherapy 
is the use of systemic drugs, making treatment particularly useful for cancers that have 
metastasized (American Cancer Society, www.cancer.org). This approach is beneficial 
for shrinking large tumors so that they are small enough to be removed by lumpectomy 
instead of mastectomy. These drugs, however, can also damage normal cells, which can 
leads to serious side effects. More than 100 drugs are currently available for 
chemotherapy, either alone or in combination with other drugs or treatments. These 
agents vary widely in their chemical composition, how they function, their usefulness in 
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treating specific forms of cancer, and side effects. Alkylating agents (nitrogen mustards, 
nitrosoureas) damage DNA to prevent the cancer cell from reproducing through 
modifications to the bases in the DNA backbone. Intercalating agents (cisplatin, 
carboplatin) stabilize DNA structure so that it cannot be replicated. Antimetabolites (5-
fluorouracil, capecitabine) interfere with DNA and RNA replication by substituting 
altered bases for the normal building blocks of RNA and DNA, thus inhibiting synthesis. 
Anthracyclines are compounds that interfere with enzymes involved in DNA replication. 
For example, topoisomerase inhibitors interfere with enzymes that help separate the 
strands of DNA during replication. The main chemotherapy drug that will be discussed in 
this study is paclitaxel, a mitotic inhibitor. Mitotic inhibitors stop mitosis by stabilizing 
microtubules or inhibiting enzymes from making proteins required for cell division.  
Paclitaxel is one of the most extensively utilized anti-cancer agents, with clinical 
efficacy in a wide range of cancers (Wang et al. 2000, Barni and Mandalà 2005). 
Paclitaxel acts to stabilize microtubules, thus inhibiting cell proliferation at the 
metaphase/anaphase boundary (Rowinsky 1997, Jordan and Wilson 1996, Mo et al. 
2003). The disruption of normal microtubule function halts mitosis and interferes with 
several critical interphase functions, ultimately leading to cell death (Rowinsky 1997).  
However, the success of paclitaxel in the clinical setting can often be inhibited by drug 
resistance, which severely limits the effectiveness of chemotherapy. While the exact 
mechanisms of resistance remain unclear, resistance is considered to be mediated by 
altered drug uptake, variations in tubulin structure, and evasion of apoptotic pathways 
(Fojo and Menefee 2007). Importantly, the design of new therapeutic regimens is 
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necessary, due to the fact that paclitaxel has negative effects on normal, as well as cancer 
cells.  
 
Molecular targeted therapy 
Molecular targeted therapy is a technique that blocks the growth of cancer cells by 
interfering with specific molecules/gene products needed for tumor growth. These 
targeted cancer therapies may be more specific and effective than current 
chemotherapeutic treatments and less harmful to normal cells. There are several types of 
targeted therapeutics, most of which are monoclonal antibodies and small molecule 
inhibitors. Important targets include the growth factors and their receptors, such as 
epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), 
and HER2. The research presented within this dissertation will focus in on trastuzumab, a 
monoclonal antibody against the extracellular portion of HER2. 
Trastuzumab (Herceptin™) binds the extracellular portion of HER2 and is 
thought to induce antibody-dependent cellular cytotoxicity, prevent receptor activation 
and signaling, inhibit angiogenesis, and induce apoptosis (Ross et al. 2004, Hudis 2007). 
Trastuzumab has become an important therapeutic option for patients with HER2-
positive breast cancer and is widely used for treating advanced metastatic disease (Sledge 
2004, Ross et al. 2003). Importantly, trastuzumab works well in combination with many 
chemotherapeutic agents (Slamon et al. 2001, Nicolini et al. 2006, Pegram et al. 2004).  
Trastuzumab administration, however, can be associated with adverse side effects 
including ventricular dysfunction, cardiac failure, infusion reactions, and pulmonary 
events (Sledge 2004, Pegram et al. 2004). In addition, not all HER2 overexpressing 
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breast cancer cells respond to trastuzumab treatment and resistance develops rapidly in a 
large number of patients (Menendez et al. 2005, Burstein 2005, Tan et al. 1997, Nahta et 
al. 2007a).  
The ability to escape cell death has important implications in cancer development 
and treatment. Successful treatment with therapeutics is largely dependent on the ability 
of an agent to trigger cell death, typically through the induction of apoptosis, although 
this may not be the only form of cell death associated with cancer therapy (Eom et al. 
2005, Okada and Mak 2004). Mutations in genes associated with the induction of death 
give cancer cells a growth advantage, allowing these cells to become invasive (Okada and 
Mak 2004). The migration of cancer cells to distant sites represents the most dangerous 
aspect of cancer, with metastatic breast cancer being responsible for approximately 90% 
of breast cancer related deaths. Median survival after appearance of metastases is 
approximately 2-3 years. Metastatic disease is largely incurable and the goal of standard 
therapies is to alleviate symptoms and prolong symptom-free survival (Welch et al. 2002, 
Barni and Mandalà 2005).  
Conventional therapeutics have proven to be initially effective in most cancer 
patients, although many relapse (Li et al. 2008). Tumor re-growth and disease relapse 
appear to be due to the development of resistance to therapy, or insufficient primary 
therapy, which decreases sensitivity, or to the existence of a subset of intrinsically 
resistant cancer cells. Therefore, it is important to investigate novel therapeutics that 
target potentially resistant cells as well as those cells capable of metastasizing. 
Furthermore, understanding the mechanisms underlying the response to therapeutics is 
vital for devising new strategies for the treatment of cancer that have longer lasting 
20 
effects on cancer cells while limiting the effect to normal cells. One prevalent area of 
research is the discovery of biomarkers that have the potential to guide treatment in 
patients to provide the greatest possible chance for survival. Biomarkers have been 
defined as any measurable factor that signals for malignancy or the potential for 
malignancy, or predicts cancer behavior, prognosis, or response to therapy (Hinestrosa et 
al. 2007). One potential biomarker is telomerase, as activity increases during cancer 
progression (Hoos et al. 1998, Herbert et al. 2001). Reactivation of telomerase can 
therefore be associated with disease development and progression. Importantly, 
telomerase activity is measured through easily interpreted assays, which is an important 
aspect of biomarker assessment in breast cancer treatment.  
 
Targeting telomerase and telomere maintenance: a novel anticancer strategy 
 Telomerase activity can be detected in 85-90% of human tumors, but not in most 
normal cells, making telomerase an attractive target for cancer therapy, regardless of 
tumor histology (Kim et al. 1994). It is possible to directly or indirectly target telomerase 
activity by inhibiting hTERT or hTR expression or function, or by targeting telomerase 
interactions with the telomere (Figure 1.4). Additionally, taking advantage of hTERT 
reactivation in cancer cells enables the use of vaccines that signal the immune system to 
specifically destroy cells expressing hTERT antigens (Shay and Wright 2006, 
Vonderheide et al. 2002, Nair et al. 2000, Vonderheide 2008). The most widely studied 
telomerase inhibitors are agents that target hTERT, hTR, telomerase-associated proteins, 
and the accessibility of active telomerase to telomeres. 
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Figure 1.4. Telomerase offers multiples targets for inhibition of enzyme function. 
Inhibition of telomerase activity can be achieved through a variety of methods. This 
includes inhibiting transcription or translation of hTERT and hTR, inhibiting the function 
of the telomerase complex, and inhibiting association between telomerase and the 
telomere.  
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There are several ways to target the catalytic function of telomerase through 
inhibition of hTERT expression or activity. The expression of a dominant negative 
hTERT (DN-hTERT) in immortalized or cancer cells results in telomerase inhibition and 
progressive telomere shortening, followed by cell growth inhibition and death due to 
telomere dysfunction (Hahn 1999, Zhang et al. 1999). The use of small interfering RNAs 
(siRNAs) also inhibits telomerase activity and sensitizes cancer cells to irradiation and to 
chemotherapy (Masutomi et al. 2005, Nakamura et al. 2005). There are a variety of non-
nucleoside agents that have anti-telomerase activity as well, resulting in decreased 
proliferation and the induction of a senescence-like phenotype after long-term treatment 
due to progressive telomere shortening (Saretzki 2003, Kelland 2005). This class of 
agents includes reverse transcriptase inhibitors (i.e., azidothymidine, or AZT, a 
compound used in HIV treatment) that have anti-telomerase activity; however, these 
effects are not specific for telomerase over other polymerases. Additionally, these 
compounds generally require high doses to effect cell growth and viability, and often 
result in nonspecific cellular toxicity (Kelland 2005, Strahl and Blackburn 1994, Strahl 
and Blackburn 1996). One of the most widely studied compounds of this class is 
BIBR1532 (2-[(E)-3-naphthalen-2-yl-but-2-enoylamino]-benzoic acid), a highly specific, 
non-competitive catalytic inhibitor that is mechanistically similar to inhibitors of HIV 
reverse transcriptase (Zimmermann and Martens 2007, Pascolo et al. 2002). The long lag 
phase associated with this type of inhibition (up to 100 days) is expected for a classical 
telomerase inhibitor, but may not be clinically relevant for effective cancer treatment 
(Kelland 2005, Zimmermann and Martens 2007, Saretzki 2003). 
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Targeting hTR rather than hTERT can be advantageous, as hTERT has been 
implicated to have extracurricular activities in addition to its well characterized role in 
telomere maintenance (Chang and DePinho 2002). The focus of the research presented 
herein will involve a specific antisense oligonucleotide telomerase template antagonist, 
GRN163L (Figure 1.5a). This compound acts to inhibit telomerase activity through 
binding hTR, thus interfering with the telomerase complex binding to the telomere 
(Figure 1.5b). Telomerase template antagonists also inhibit the enzymatic activity of 
telomerase rather than inhibiting protein translation, and thus would not interfere with 
other functions of the telomerase complex (for example, involvement in DNA repair). 
The sequence of the hTR template region is known (5'-CUAACCCUAAC-3'), 
simplifying the design of oligonucleotide-based inhibitors. The knowledge of this 
sequence also makes the development of mismatch oligonucleotides possible. GRN163L 
is a second generation, lipid-conjugated N3'→P5' thio-phosphoramidate oligonucleotide 
containing a palmitoyl lipid group at the 5' terminal end of its sequence. This type of 
modification and chemical backbone enhances the stability of the oligonucleotide against 
nuclease digestion, enhances binding to proteins, and improves cellular uptake (Herbert 
et al. 2005). GRN163L has been shown to efficiently inhibit telomerase activity in 
immortalized and cancer cells, indicating its potential for use as a cancer therapeutic 
(Djojosubroto et al. 2004, Herbert et al. 2005). Recently, published reports have found 
dramatic effects of GRN163L, compared to earlier generations of telomerase template 
antagonists, on cancer cell growth inhibition before the bulk of the telomeres would have 
theoretically reached critical shortening, as measured by Southern hybridization methods 
(Dikmen et al. 2005, Hochreiter et al. 2006, Gellert et al. 2006). The mechanisms 
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underlying the response to GRN163L are not completely understood; therefore, it is of 
interest to further elucidate the mechanisms of GRN163L for the development of new 
cancer therapeutic regimens.   
 
The use of telomerase inhibition in cancer therapy 
 The original hypotheses for targeting telomerase in cancer have been supported by 
a large body of work demonstrating that telomerase inhibition resulted in the erosion of 
telomeric DNA, eventually leading to apoptosis or senescence (Hahn et al. 1999, Zhang 
et al. 1999, Herbert et al. 1999, Herbert et al. 2005, Gellert et al. 2006 for review, Shay 
2003 for review). This effect is expected to be relatively specific to cancer cells with few 
side effects for somatic cells and stem cells, as cancer cells typically have shorter 
telomeres than those found in normal tissue (Shay and Wright 2007, Gellert et al. 2005, 
Shay and Wright 2006). In vivo studies have demonstrated that telomerase inhibition not 
only inhibits the growth of primary tumors, but also inhibits cancer metastases to the lung 
(Hochreiter et al. 2006, Jackson et al. 2007).   
 As described in this chapter, inhibition of telomerase activity can be achieved in a 
number of ways (Figure 1.4). At the present time, few of these agents have reached 
clinical trials. Original in vitro studies utilizing telomerase inhibitors demonstrated a lag 
phase before critical telomere shortening and cell growth inhibition (Hahn et al. 1999, 
Zhang et al. 1999, Herbert et al. 1999). Recent reports, however, have demonstrated that 
the new generation of telomerase inhibitors, particularly the lipid-conjugated 
oligonucleotides, may target cancer cell growth more efficiently than previously expected 
(Herbert et al. 2005, Hochreiter et al. 2006, Jackson et al. 2007). These findings may 
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Figure 1.5. GRN163L binds to hTR, inhibiting telomerase from recognizing its 
telomeric substrate. (A) Structure of GRN163L. GRN163L is a 13-mer lipidated 
N3'→P5' thiophosphoramidate oligonucleotide containing a palmitoyl group at the 5' 
terminal end of its sequence (5' -TAGGGTTAGACAA-3'). (B) GRN163L is 
complementary to the intrinsic template region (3'-CAAUCCCAAUC-5') of the RNA 
component of telomerase, hTR. Binding of GRN163L to hTR inhibits association with 
telomeric DNA. 
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provide an increased chance for therapeutic value with low doses of drug, as well as a 
better therapeutic window for the use of other therapies in order to limit the amount of 
toxicity in normal cells. Telomerase inhibitors were originally proposed to be used in 
addition to other therapeutic regimens to prevent recurrent disease or metastasis after 
primary therapy. The current knowledge about the efficacy of telomerase inhibition is 
promising for the use of these compounds as cancer therapeutics. However, the 
mechanisms underlying the response to telomerase inhibition remain unclear. Additional 
studies are needed to fully comprehend how to appropriately and effectively use these 
compounds. An important consideration for the use of telomerase inhibition based 
therapeutics is the emergence of cell populations utilizing other methods of telomere 
maintenance, such as the ALT pathway. Although cells exploiting the ALT pathway have 
not been observed in human cancer cell lines after treatment with telomerase inhibitors, 
this possibility remains an important potential in the development of therapeutic 
resistance, particularly if the use of telomerase inhibitors will be chronically required to 
control primary cancer cell growth and metastasis (Hahn 2003). 
  GRN163L, the primary telomerase inhibitor discussed in this research, has been 
in Phase I/II clinical trials for patients with chronic lymphocytic leukemia (CLL) since 
2005 and for solid tumor malignancies since 2006 (www.clinicaltrials.gov). Phase I trials 
have revealed that weekly administration of GRN163L is well tolerated by patients with 
no dose-limiting toxicities or serious adverse side effects yet reported. More importantly, 
there has been a beneficial effect of treatment in multiple patients with CLL, with stable 
disease and tumor lysis syndrome both being reported. Based on recent results from those 
studies and recent observations on myeloma cancer stem cells, a fourth clinical trial for 
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GRN163L was initiated in late 2007 for multiple myeloma patients. Importantly for this 
research, a Phase I/II trial with GRN163L in combination with paclitaxel and 
bevacizumab (anti-angiogenesis agent) has just been initiated for patients with locally 
recurrent or metastatic breast cancer. 
  
Research aims and significance 
Published reports have shown a significant correlation between telomerase 
activity and tumor size, lymph node status, and disease stage in breast cancer.  
Telomerase activity increased in primary carcinomas with ongoing tumor progression 
(Hoos et al. 1998, Herbert et al. 2001). Furthermore, telomere lengths in cancer cells are 
shorter than in the surrounding normal tissue (Meeker et al. 2004). These findings 
support the hypothesis that telomerase is essential for cancer cell survival. The 
telomerase template antagonist GRN163L has been shown to efficiently inhibit 
telomerase activity in cancer cell lines, reduce breast tumor growth and metastasis, and 
limit adhesion to culture substrates (Herbert et al. 2005, Hochreiter et al. 2006, Jackson et 
al. 2007).  
The mechanisms of cancer cell growth inhibition via GRN163L, however, are not 
completely understood. In addition to inhibition of telomerase activity, telomere 
maintenance, and cell proliferation, preliminary results indicate that exposure to 
GRN163L alters cellular structure and stability in cancer cells. The overall goal of this 
research project was to further elucidate the mechanisms of GRN163L to support the 
central hypothesis that the telomere dysfunction, structural and proliferative changes in 
breast cancer cells induced by GRN163L can synergize with other forms of conventional 
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cancer therapy to inhibit the tumorigenicity of breast cancer cells both in vitro and in 
vivo.  The aims of this research were accomplished by: 1) determining the effects of 
combining telomere dysfunction induced by GRN163L with a DNA damage inducer 
(irradiation); 2) elucidating the mechanisms underlying the cellular response to 
GRN163L and the effect of combination therapy with the mitotic inhibitor paclitaxel; and 
3) testing the hypothesis that a telomerase inhibitor can augment the effects of 
trastuzumab in breast cancer cells with HER2 amplification. The combination of 
telomerase inhibition via GRN163L and irradiation (IR) was shown to significantly 
enhance the effects of radiation on breast cancer cell growth in vitro and primary tumor 
growth in vivo (Chapter Two; Gomez-Millan et al. 2007). The increased sensitivity to IR 
was due to induced telomere dysfunction, suggesting a relationship between extended 
telomerase inhibition, telomere length, and inhibition of DNA damage-induced repair. 
Furthermore, this research demonstrates that in addition to the known telomere 
dysfunction effects from continuous telomerase inhibition, GRN163L induces a rapid 
inhibitory effect on cell growth and invasion. This rapid response synergistically inhibits 
the growth of breast cancer cells in vitro and in vivo with paclitaxel and trastuzumab, 
supporting the use of this compound in the clinical setting. Combining GRN163L with 
these three therapies can not only aid in determining whether the effects on cell growth 
inhibition can be synergistic, but can also provide insights into the mechanism of action 
of GRN163L.  In addition, the results of this work not only compliment the development 
of mechanism-based combination treatments with GRN163L, but also improve the 
understanding of the role of telomerase (activity) in cancer. Furthermore, by elucidating 
the effects of GRN163L alone and in combination with other therapeutics, biomarkers 
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can be designed for monitoring the response to treatment or disease progression. The use 
of multiple agents in combination often results in therapeutic synergy, which may be able 
to overcome drug resistance in a large number of cancers. Using these combination 
therapies is likely to improve treatment regimens, as targeting multiple pathways 
involved in cancer progression is likely to increase patient survival over single drug 
therapy. However, current combination therapies often rely on methods that are toxic to 
both normal and cancer cells. The use of GRN163L and the combination treatments 
proposed in this study could thus reduce the negative side effects of chemotherapeutic 
drugs and mortality due to metastatic disease.  
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Chapter Two 
Telomerase Template Antagonism and Telomere Dysfunction via GRN163L 
Increases Radiation Sensitivity in Breast Cancer Cells 
This work is reprinted in part from Int J Radiat Oncol Biol Phys, Jaime Gomez-Millan, 
Erin M. Goldblatt, Sergei M. Gryaznov, Marc S. Mendonca, and Brittney-Shea Herbert, 
“Telomere Dysfunction Induced by GRN163L Increases Radiation Sensitivity in Breast 
Cancer Cells”, Vol. 67:897–905 (2007) with permission from Elsevier. 
 
Abstract 
Telomerase activity can be detected in 85-90% of human tumors, which stabilizes 
telomeres and prevents apoptosis or senescence due to genomic instability. There has 
been a link between telomerase, telomeres, and DNA repair, as DNA repair proteins can 
be found at the telomeres, and dysfunctional telomeres induce a DNA damage response. 
Irradiation (IR) induces lethal DNA damage and double-stranded breaks, thus suggesting 
that the combination of telomerase inhibition and IR may be synergistic. Our lab utilizes 
the telomerase template antagonist GRN163L, which is complementary to the template 
region of the telomerase ribonucleic acid component (hTR). The objective of this study 
was to determine whether exposure to GRN163L enhances radiation sensitivity in human 
breast cancer cells through inhibition of telomerase activity and gross telomere 
dysfunction. Results demonstrate that GRN163L inhibits telomerase activity and shortens 
telomeres, as well as alters cell cycle phase distribution, of MDA-MB-231 breast cancer 
cells. Additionally, telomere dysfunction induced by GRN163L enhances the effects of 
IR in vivo, with a significant decrease in tumor growth of MDA-MB-231 breast cancer 
cells in mice when exposed to GRN163L plus IR. These results indicate that GRN163L is 
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a promising adjuvant treatment in combination with radiation therapy that may improve 
the therapeutic index by enhancing the radiation sensitivity.  
 
Introduction 
Telomeres are repetitive (TTAGGG)n sequences found at the end of chromosomes 
(Figure 1.1, page 3) that act as protection from chromosomal recombination, end to end 
fusions, and recognition as damaged DNA (Blackburn 2001, Cong et al. 2002). 
Telomerase is a ribonucleoprotein complex that acts to maintain telomeres by replacing 
the sequences lost in during each round of DNA replication (Figure 1.2, page 6). 
Telomerase activation can be detected in 80-90% of cancer cells, whereas most somatic 
human cells do not have telomerase activity (Cong et al. 2002, Shay and Bacchetti 1997). 
This makes telomerase inhibition an attractive treatment for cancer therapy. Targeting the 
RNA template of telomerase (hTR) using small antisense oligonucleotides prevents the 
activity of the telomerase enzyme (Shay and Wright 2006). The most well-studied 
compound in this class is GRN163L, a N3'→P5' thio-phosphoramidate that stably binds 
hTR (Figure 1.5, page 25), is resistant to degradation, and has both high affinity and 
specificity for targets (Herbert et al. 2005). This method of action makes GRN163L a 
unique telomerase inhibitor as it blocks the biochemical activity of telomerase as opposed 
to inhibiting hTERT protein expression. This compound is a potent inhibitor of 
telomerase activity and tumorigenicity in vitro, and has been shown to be effective in 
reducing tumor growth in vivo (Dikmen et al. 2005, Herbert et al. 2005, Djojosubtruto et 
al. 2005, Gellert et al. 2006, Hochreiter et al. 2006). One common problem with using 
small molecule inhibitors of hTERT or hTR is that many require long treatment times, 
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and response is dependent upon initial telomere lengths (Sarezki 2003, Kelland 2005, 
Zimmermann and Martens 2007). Although this indicates that telomerase inhibitors may 
not be used for single agent therapy, there have been numerous reports that suggest that 
telomerase inhibition can sensitize cells to chemotherapy or irradiation (Ward and 
Autexier 2005, Cerone et al. 2006a, Djojosubruto et al. 2005, Kelland 2005, Gellert et al. 
2005, Gomez-Millan et al. 2007, Zimmermann and Martens 2007).   
Ionizing radiation (IR) is an important therapeutic modality that induces DNA 
damage and double-stranded breaks that are lethal to the cells when the damage cannot be 
repaired (Bernier et al. 2004). Although radiation therapy is well tolerated, several 
adverse effects have been reported. This can include skeletal complications, radiation 
induced heart disease, and lung disease (Hirbe et al. 2006, Munshi 2007). IR after 
lumpectomy is widely accepted as a standard of care for early stage breast cancer. In 
early-stage breast cancer, radiation significantly reduces the risk of local recurrences 
(Haffty et al. 2006). In cases of invasive disease, adjuvant chemotherapy precedes IR, as 
these two therapeutic techniques are not generally used together due to added toxicities. 
However, delayed IR may increase the risk of relapse in some subsets of patients. In a 
retrospective study performed in 2006, Haffty et al. report that concurrent IR and 
chemotherapy resulted in improved relapse rates and lower toxicity than sequential IR 
and chemotherapy (Haffty et al. 2006). This study, however, was performed using a 
chemotherapeutic regimen that is no longer routinely used, demonstrating the need to 
study the use of IR with new therapeutic agents.  
There is a link between telomeres and DNA damage, as components of DNA 
damage response pathways have been found at the telomeres. Additionally, previously 
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published reports indicate a possible role of telomerase in DNA repair independent of its 
role in maintaining telomere length. Ectopic expression of hTERT in normal cells 
enhanced DNA repair, and these cells also had a lower mutation rate (Sharma et al. 2003, 
Shin et al. 2004). This suggests that the association of telomerase inhibition and IR may 
be synergistic. Nakamura et al. demonstrated that siRNA specific for hTERT increased 
sensitivity of cancer cells to IR or DNA damage inducing chemotherapeutic agents 
(Nakamura et al. 2005). The purpose of the study herein was to determine the effects of 
combining GRN163L-induced telomere dysfunction and IR. The goal was to determine 
whether the enzymatic inhibition of telomerase by GRN163L enhances sensitivity of 
breast cancer cells to IR, and whether this enhancement depends on the induction of 
telomere dysfunction induced by GRN163L. This was the first study that investigated the 
interactions between IR and telomerase inhibition via GRN163L in human breast cancer 
cells. 
 
Results 
GRN163L efficiently inhibits telomerase activity and reduces telomere length in MDA-
MB-231 breast cancer cells 
Telomerase activity and processivity was measured using the polymerase chain 
reaction (PCR) based telomere repeat amplification protocol (TRAP) by introducing 
telomerase in cell lysates to an artificial “telomere”. If telomerase is present and 
functional in cell lysates, the enzyme will be able to elongate and amplify the telomeric 
substrate. To test the effects of GRN163L on telomerase activity in breast cancer cells, 
MDA-MB-231 cells were treated with GRN163L for 9-42 days and passaged weekly. To 
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ensure continual telomerase inhibition, cells were treated with fresh drug every third day. 
Telomerase activity was measured at three different time points representing early, mid, 
and late passages after initiation of treatment with GRN163L. The TRAP assay showed 
an absence of telomerase activity after 9, 20, and 42 days compared to untreated cells, 
indicating that resistance to GRN163L did not develop (Figure 2.1).  
To confirm that telomerase inhibition results in progressive telomere shortening, 
the average telomere length was measured after 9, 20, and 42 days of treatment using the 
telomere/terminal restriction fragment (TRF) assay. To measure telomeric DNA, 
genomic DNA was isolated from MDA-MB-231 cells, and digested with a mixture of 
restriction enzymes to isolate telomeric DNA (TTAGGG/CCCTAA sequences). This 
DNA was used in a modified Southern gel hybridization with a radiolabeled telomeric 
probe. The average telomere size was determined by the mean of the fragment lengths 
per sample. As expected, there was a progressive reduction in the average telomere 
length with continued exposure to GRN163L over time. In the cells treated for 42 days, 
the average telomere length was reduced from 3.0 to 2.5 Kb (Figure 2.2). Mismatch 
oligonucleotide treatment did not exhibit any effect on telomere length (data not shown). 
The measured telomere length using the Southern hybridization-based TRF assay may 
underestimate the actual loss of telomeric DNA, as this assay may not accurately measure 
subtelomeric regions or critically short telomeres. However, similar decreases in telomere 
length have been shown to have biological effects on cell growth (Herbert et al. 1999). 
Additionally, published reports demonstrate that a small number of short telomeres may  
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Figure 2.1. Measurement of telomerase activity in cells treated with GRN163L. 
Telomerase activity was measured via the TRAP assay with 500 cell equivalents per lane 
using a fluorescently labeled oligonucleotide primer. Five-hundred cell equivalents from 
MCF-7 cells served as positive control (+ control) for the assay. Lysis buffer alone (LB) 
and heat inactivated (HI) MCF-7 cells served as negative controls. Telomerase activity, 
as represented by the 6-bp incremental ladder of telomerase products above the internal 
standard control (IC) band, remained inhibited throughout treatment compared to 
untreated (media only) MDA-MB-231 cells (UT).  
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Figure 2.2. Measurement of telomere length in cells treated with GRN163L. (A) 
Average telomere length was measured in untreated (media only) MDA-MB-231 cells 
and in cells treated with GRN163L for 9, 20, or 42 days using a modified in-gel Southern 
hybridization of digested genomic DNA. (B)  Average telomere length (in kb) decreased 
0.5 kb in size for cells treated for 42 days with GRN163L compared with untreated cells. 
TRF = telomere/terminal restriction fragment. 
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be responsible for cell viability rather than the average telomere length (Hermann et al. 
2001). 
 
GRN163L reduces cell proliferation and induces a G2 cell cycle shift in MDA-MB-231 
cells 
With continuous treatment of GRN163L and progressive telomere shortening, 
MDA-MB-231 breast cancer cells exhibit a reduction in cell proliferation and population 
doubling levels compared to controls (Chapter Three; Hochreiter et al. 2006, Gomez-
Millan et al. 2007).  The decrease in cell proliferation and plating efficiency may be 
explained by an inhibition in proper cell cycling. Arrests in any phase of the cell cycle 
can inhibit proper proliferation rates and therefore explain the decrease in cell growth and 
replication. Cells treated with GRN163L for 9-42 days were collected for cell cycle 
analysis. Untreated MDA-MB-231 cells had a phase distribution of 45.5% in G1, 32.6% 
in S, and 21.9% in G2. There was a significant increase in G2 was shown in cells treated 
for 9 and 20 days compared with controls (Table 2.1). After 9 days treatment with 
GRN163L, the percentage of cells in G2 increased to 40.9%, while the percentage of 
cells in G1 decreased to 31.4%. A similar trend was found after 20 days of treatment, 
with 40.9% of cells in G2 and 28.5% of cells in G1. Interestingly, there is a similar cell 
cycle phase distribution between controls and cells treated for 42 days. Cells treated for 
42 days had a distribution of 47.1% in G1, 29.9% in S, and 23.15% in G2. 
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Table 2.1 Cell cycle phase distribution after treatment with GRN163L 
 
 
 
 G1 S G2/M 
Untreated 45.5% 32.6% 21.9% 
9 days 31.4% 28.6% 40% 
20 days 28.5% 25.4% 46.1% 
42 days 47.1% 29.9% 23.15% 
 
 
 
 
 
MDA-MB-231 cells were treated with GRN163L for 9-42 days prior to collection for cell 
cycle analysis. Cells were stained with propidium iodide prior to determining cell cycle 
distribution using FACScan. Results were analyzed using the ModFit LT program to 
determine percentage of cells in each cell cycle phase (Verity Software House Inc). 
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GRN163L sensitizes breast cancer cells to irradiation in vivo 
Gomez-Millan et al. have demonstrated that while MDA-MB-231 cells are 
sensitive to radiation, treatment with GRN163L can significantly enhance radiation 
sensitivity (Gomez-Millan et al. 2007). This effect was demonstrated through clonogenic 
assays to measure proliferative capability after treatment with GRN163L and IR. While 
exposure to GRN163L for 9-20 days did not affect colony formation ability, cells with 
telomere dysfunction induced by GRN163L after 42 days of treatment had significantly 
reduced colony formation ability. Additionally, it was reported that the combination of 
GRN163L and IR can inhibit DNA repair, as evidenced by decreased survival after 
combination therapy versus either GRN163L or IR alone. Again, this was determined to 
be due to telomere dysfunction after long-term treatment with GRN163L (Gomez-Millan 
et al. 2007). 
It has been suggested that radiotherapy treatment can accelerate repopulation of 
proliferative tumor cells during the course of the treatment. This acceleration has been 
suggested as one of the primary causes of tumor recurrence after radiation therapy 
(Bentzen and Thames 1991). To determine whether the addition of GRN163L can 
improve the effectiveness of IR on tumor growth in vivo, combination therapy on the 
growth of xenograft MDA-MB-231 tumors were investigated. MDA-MB-231 cells 
cultured with or without mismatch oligonucleotide (MM) for seven weeks were injected 
into the left and right flanks, respectively, of 14 mice. In 14 separate mice, MDA-MB-
231 cells cultured with GRN163L for 7 weeks were injected into the right flanks. Mice 
were divided into treatment groups (n=7 per group): untreated (UT), mismatch (MM)-
alone, IR-alone, MM+IR, GRN163L-alone, and GRN163L + IR. Once tumors reached 
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~50 mm3 (13 days post injection), mice receiving GRN163L were treated with 30 mg/kg 
(indicated in Figure 2.3 by white arrows). The following day, mice were treated with a 
clinically relevant dose of 6 Gy irradiation (indicated in Figure 2.3 by the gray arrow). A 
second in vivo dose of GRN163L was administered 4 weeks post-injection. GRN163L-
treated MDA-MB-231 cells displayed a lag in tumor growth compared with the 
xenografts of untreated or mismatch control-treated cells (Figure 2.3; p = 0.0005 and 
0.00019, respectively). MDA-MB-231 tumors subjected to a clinically relevant dose of 6 
Gy irradiation regressed within 1 week post-irradiation and maintained a lag in tumor 
growth compared with MDA-MB-231 untreated, mismatch-alone, and GRN163L-alone 
treated xenografts. More importantly, the combination of GRN163L and IR resulted in a 
highly statistically significant difference in tumor growth compared to mice receiving IR 
alone or IR + MM (Figure 2.3; p = 1.8 x 10-6 and 1.3 x 10-4, respectively). GRN163L was 
well tolerated by the mice, and the animals did not show any health or behavioral 
problems. After 80 days, all 7 mice (100%) in the GRN163L plus IR group survived 
compared with a 14-52% survival in the other groups.  
 
Discussion 
GRN163L, a telomerase template antagonist currently in clinical trials, binds to 
hTR (Figure 1.5, page 25) and inhibits the enzymatic activity of telomerase, resulting in 
telomere shortening as a cell divides. The results presented here demonstrate that 
exposure to GRN163L progressively shortens the average telomere length, resulting in a 
reduction in the proliferation rate of cancer cells and a decrease in plating efficiency. 
Additionally, this is the first time the effects of GRN163L and radiation have been 
studied in breast cancer cells. The combination of telomere dysfunction induced 
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Figure 2.3. Efficacy of GRN163L in combination with irradiation in an MDA-MB-
231 xenograft tumor model. Tumor growth rate of untreated (UT), mismatch-treated 
(MM), or GRN163L-treated MDA-MB-231 cells with or without the combination of 
irradiation (IR) is shown (n = 7 per group). Cells were pre-treated for seven weeks with 
oligonucleotides prior to injection. Data are presented as mean tumor volume ± SE. 
White arrows indicate administration of GRN163L. Gray arrow indicates date of 
irradiation treatment. (*) Represents a statistical difference between the group receiving 
ionizing radiation alone  or MM + IR vs. the group receiving the combination of 
GRN163L and ionizing radiation (p = 1.8 x 10-6 and 1.3 x 10-4, respectively). Ionizing 
radiation alone vs. IR + MM, p = 0.267.  
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by GRN163L significantly enhances the effects of radiation on breast cancer cell growth 
in vitro (data not shown; Gomez-Millan et al. 2007) and primary tumor growth in vivo (in 
the present study).  
The cell cycle is highly important in determining sensitivity to IR, as the response 
to DNA damage is the activation of cell cycle checkpoints (Pawlik and Keyomarsi 2004, 
Samuel et al. 2002). Cells are most radiosensitive in the G2 phase of the cell cycle, less 
sensitive during G1, and least sensitive during S phase. Many chemotherapeutic drugs 
arrest cells in G1 or G2, thus helping to explain the increasing sensitivity to IR after 
treatment (Pawlik and Keyomarsi 2004). After 9-20 days of treatment with GRN163L, 
there was an increase in the percentage of cells in the G2 phase of the cell cycle, 
suggesting difficulty in fully progressing through the cell cycle. This effect could be a 
result of an overall lengthening of the G2 phase, or the induction of tetraploid cells with a 
limited ability to proliferate. However, we did not observe an increase in radiosensitivity 
in cells treated with GRN163L for 9-20 days prior to irradiation despite the increase in 
the percentage of cells in G2 (data not shown; Gomez-Millan et al. 2007).  It is possible 
that the increase in the number of cells in G2 alone was not significant enough to 
sensitize the entire population to IR and that a significant amount of telomere dysfunction 
was needed to induce DNA damage, thus explaining why we do not find significant 
benefit of GRN163L on sensitivity to IR at these time points (data not shown; Gomez-
Millan et al. 2007). 
In cells exposed to GRN163L for 42 days, cell cycle distribution is similar to 
untreated cells. There is, however, a significant drop in the plating efficiency (PE) and an 
increase in doubling time (data not shown; Gomez-Millan et al. 2007), indicating a 
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significant reduction in the proliferative capacity of treated cells. In addition to the 
substantial reduction in PE compared with control cells, there was telomere shortening, 
which could help explain the decrease in proliferation and PE, as short telomeres can be 
recognized as damaged DNA. Critically short telomeres may not be accurately measured 
in the TRF assays (providing average telomere lengths) if present in small numbers; 
however, these telomeres can be measured through fluorescence in situ hybridization 
(FISH). Using this method has allowed for the association of critically short telomeres 
and DNA damage foci in a cell. These short telomeres can trigger growth arrest or cell 
death without affecting the average telomere size. These observations are also supported 
by published reports demonstrating that a small number of short telomeres are 
responsible for cell viability rather than the average telomere length (Zou et al. 2004, 
Ouellette et al. 2000, Hermann et al. 2001). It is also possible that telomere dysfunction 
induced by GRN163L prior to IR induces mitotic catastrophe, which is a type of cell 
death that occurs during mitosis as a result of DNA damage or abnormal spindle 
formation (Eom et al. 2005). Mitotic catastrophe is thought to result from a combination 
of deficient cell-cycle checkpoints and cellular damage, resulting in failure of cell cycle 
arrest before or at mitosis. This would trigger cell division with faulty chromosome 
segregation, resulting in cells with abnormal DNA content (Eom et al. 2005, Castedo et 
al. 2004). The loss of cells due to induction of mitotic catastrophe after 42 days of 
treatment with GRN163L could explain the reduction in plating efficiency.  
DNA repair is active during the G2 phase of the cell cycle, where double strand 
breaks are recognized and repaired. At this time, functional telomeres may be recognized 
by DNA repair machinery and would be accessible to repair enzymes. This association 
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with DNA repair proteins may be necessary for telomere maintenance (Verdun et al. 
2005). This response, however, does not typically lead to general DNA damage 
responses, therefore not resulting in a continued cell cycle arrest. After 9-20 days of 
treatment with GRN163L, telomeres have most likely not reached a critically short state, 
thus remaining functional. Thus, the increase seen in the percentage of cells in G2 may be 
due to cells undergoing DNA repair. After 42 days of treatment with GRN163L, 
telomeres are more likely to have reached a critically short length, thus limiting the 
association of DNA repair proteins. At this time point, the cell cycle distribution is 
similar to that of untreated cells; however, there is a significant benefit from the addition 
of telomere dysfunction induced by GRN163L and IR. This synergistic response is most 
likely due to overwhelming the cells with DNA damage (induced by telomere 
dysfunction and IR), as wells as inhibiting telomerase from participating in DNA repair 
(Sharma et al. 2003, Shin et al. 2004). This hypothesis supports the idea that the change 
in cell cycle distribution observed after 9-20 days of treatment may not be contributing to 
GRN163L induced IR sensitivity. The loss of cells due to mitotic catastrophe could 
explain the similarities in the cell cycle distribution between untreated control cells and 
cells treated with GRN163L for 42 days; i.e., cells that could not repair damage and 
therefore cycle properly may have been eliminated from the population, leaving only 
cells that could bypass cell-cycle checkpoints. Additionally, it has been hypothesized that 
DNA double-strand breaks induce repair through homologous recombination (HR), using 
the material from a partner chromosome as a template to repair the damaged region. 
Indeed, telomerase deficiency has been reported to increase the rate of chromosomal 
relocations via homologous recombination in yeast, further implicating the role of 
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telomerase in global genomic stability. Furthermore, telomerase-deficient mice are 
hypersensitive to IR and demonstrate a delay in DSB repair that may reflect a defect in 
HR (Meyer and Bailis 2008). These findings support the data presented herein; 
telomerase inhibition may inhibit DNA repair via HR, resulting in cell death due to DNA 
damage. The cell cycle distribution seen after 42 days of treatment with GRN163L could 
therefore reflect the population of cells still able to repair DNA damage and cycle 
properly. 
hTERT has a reported role in recruiting DNA repair proteins to damaged DNA 
sites in fibroblasts (Sharma et al. 2003, Shin et al. 2004). Ectopic expression of hTERT 
enhances repair of IR induced DNA damage in fibroblasts independently of telomere 
length (Sharma et al. 2003). Conversely, hTERT suppression in fibroblasts alters 
chromatin structure and DNA damage response to IR and sensitize cells to IR (Nakamura 
et al. 2005, Masutomi et al. 2005). These studies, taken together, suggest a role for 
telomerase in DNA damage repair independent of its role in maintaining telomeres. 
Telomere dysfunction induced by GRN163L sensitized breast cancer cells to radiation in 
vitro and inhibited DNA repair after the induction of telomere dysfunction (data not 
shown; Gomez-Millan et al. 2007). This is confirmed in the present studies by the fact 
that combination of GRN163L and IR significantly reduces tumor volume in vivo, 
suggesting that critically short telomeres synergize with IR to inhibit primary tumor 
growth. These results also support previous studies demonstrating that in mice lacking 
the telomerase RNA component, cells with short telomeres are more sensitive to radiation 
and that telomere dysfunction enhances the effects of IR in gastrointestinal stem cells 
(Goytisolo et al. 2000, Wong et al. 2000). Mice treated with GRN163L or IR alone 
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demonstrated an initial lag in tumor growth, followed by progressive disease. This would 
be expected, as treatment was only administered once (for IR) or twice (for GRN163L). 
Mice receiving both GRN163L and IR demonstrated a significantly reduced tumor 
volume for the bulk of the experiment, with tumor growth remaining static for an 
additional thirty days prior to observation of increased tumor volume. This indicates that 
the effect of GRN163L is reversible with the discontinuation of treatment, although the 
induction of telomere dysfunction severely inhibited tumor growth long after termination 
of therapy.  
In summary, treatment of MDA-MB-231 breast cancer cells with GRN163L 
results in the induction of telomere dysfunction in vitro and synergistically enhances 
radiation sensitivity in vivo at clinically relevant doses. These results suggest a 
relationship between extended telomerase inhibition, telomere length, and impairment of 
DNA damage induced repair. The combination of telomerase inhibitors and IR may allow 
for the use of lower doses of IR, a reduction in the overall time of treatment, and a 
decrease in secondary effects. Although treatment with GRN163L for shorter periods of 
time did not show any synergism with IR, the decrease in proliferation observed could 
also have a potential effect when combined with IR in clinical settings. Thus, the in vivo 
results with MDA-MB-231 xenografts support GRN163L as a promising adjuvant cancer 
treatment in combination with radiation therapy. With GRN163L currently in clinical 
trials, it will be of interest to further study whether other tumor models respond to 
GRN163L in combination with radiation. 
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Materials and Methods 
Cell culture and reagents 
  MDA-MB-231 breast cancer cells were cultured at 37°C and 5% CO2 in DMEM 
containing 10% cosmic calf serum and routinely checked for mycoplasma contamination.  
Cell cultures were supplemented as necessary with GRN163L or the mismatch control 
oligonucleotide. The telomerase template antagonists used in this study are 
complementary to the telomerase RNA component (hTR) template region for telomerase 
(5' -CUAACCCUAAC-3'). The lipid modified N3'→P5' thio-phosphoramidate 
oligonucleotide (GRN163L, 5' -Palm-TAGGGTTAGACAA-NH2-3') and the 5'-
palmitoyl mismatch control oligonucleotide (5' -Palm-TAGGTGTAAGCAA-NH2-3') 
were prepared as previously described (Herbert et al. 2005). Cells were treated with 1-2.5 
μM GRN163L as necessary. These doses effectively inhibit 100% telomerase activity 
within 48 hours of treatment (data not shown). 
 
Telomerase activity assay 
Telomerase activity was measured using the polymerase chain reaction– based 
Telomeric Repeat Amplification Protocol (TRAP) as previously described (Hochreiter et 
al. 2006, Herbert et al. 2006). Briefly, MDA-MB-231 cells were treated with GRN163L 
as described. Cells were collected and lysed in NP-40 lysis buffer to release the 
telomerase enzyme from cells. The telomerase in the cell lysate was combined with a 
primer resembling an artificial “telomere”. After primer extension with a Cy5 
fluorescently labeled telomerase template primer and polymerase chain reaction 
amplification, reaction products were run on a 10% nondenaturing acrylamide gel. The 
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gel was visualized, without drying, on a PhosphorImager using ImageQuant software 
(Molecular Dynamics, Sunnyvale, CA). Telomerase activity was demonstrated as a 6-bp 
telomerase-specific ladder above the 36-bp internal standard control band (IC). 
 
Telomere length assays 
Measurements of average telomere length in a population of cells were performed 
as described previously using the telomere/terminal restriction fragment (TRF) assay 
(Hochreiter et al. 2006, Oullette et al. 2000). Briefly, DNA was isolated and the proteins 
digested 4 hours followed by inactivation of proteinase K for 30 minutes at 70°C and 
dialysis at 4°C overnight. Genomic DNA was digested to completion with a mixture of 
restriction enzymes (1U/μg each of AluI, HaeIII, HinfI, MspI, and RsaI, Roche 
Boehringer Mannheim, Indianapolis, IN). The digested DNA was separated on a 0.7% 
agarose gel in 0.5X TBE. The gel was denatured for 20 minutes in 0.5 mol/L NaOH/1.5 
mol/L NaCl, rinsed with distilled H2O, dried on Whatman No. 3MM paper under vacuum 
for 1 hour at 55°C, and neutralized for 15 minutes in 1.5 mol/L NaCl, 0.5 mol/L Tris-HCl 
(pH 8.0). The gel was then probed with a radiolabeled telomeric probe for 16 hours at 
42°C in 5X SSC buffer, 5X Denhardt’s solution, 10 mmol/L Na2HPO4, and 1 mmol/L 
Na2H2P2O7. The gel was then washed once for 20 minutes in 2X SSC, twice for 15 
minutes each in 0.1X SSC at room temperature, and exposed to a phosphor screen 
(PhosphorImager). 
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Cell cycle analysis 
MDA-MB-231 cells were treated with GRN163L for 9-42 days before collection 
for cell cycle analysis as previously described (Asai et al. 2003). Briefly, 5x105 cells were 
collected and fixed in 70% ethanol. Fixed cells were washed in PBS and resuspended in 
equal volumes of 0.1 mg/mL propidium iodide and 0.5 μg/mL DNase-free RNase and 
incubated in the dark for 30 minutes on ice. Samples were filtered prior to analysis by 
FACscan and analyzed using the ModFit LT program (Verity Software House Inc). 
 
Xenograft mice studies 
Athymic nude mice (nu/nu; Harlan Sprague-Dawley, Inc., Indianapolis, IN) were 
maintained in pathogen-free conditions within the Laboratory Animal Resources Center 
at the Indiana University School of Medicine according to an approved protocol by the 
institutional Laboratory Animal Resources Center and Institutional Animal Care and Use 
Committee. Five million (5 x 106) MDAMB-231 cells cultured with or without 1 μM 
mismatch oligonucleotide (Herbert et al. 2005) for 7 weeks were injected into the left and 
right flanks, respectively, of 14 mice. In 14 separate mice, 5 x 106 MDA-MB-231 cells 
cultured with 1 μM GRN163L for 7 weeks were injected into the right flanks. Mice were 
then divided into six treatment groups (n = 7 per group): untreated (UT), mismatch 
(MM)-alone, IR-alone, MM+IR, GRN163L-alone, and GRN163L+IR. When tumors 
reached ~50 mm3 (day 14 post-injection), the flanks of mice in the GRN163L= IR (n = 
7), IR-alone, and MM+IR groups (n = 7) were subjected to 6 Gy irradiation. Tumors 
were measured twice weekly, and mice were euthanized when tumors reached ~2 cm3. 
Tumor volume was calculated as (length x width2)/2 (in mm3), and data were presented 
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as mean tumor volume ± SE. At Days 13 and 31 post-injection, mice in the GRN163L 
alone (n = 7) and GRN163L + IR groups (n = 7) were given 30 mg/kg GRN163L 
intraperitoneally (IP) to ensure inhibition of telomerase activity. Statistical analysis was 
performed using Microsoft Excel and GraphPad Prism 4.0 (GraphPad Software, Inc., San 
Diego, CA). ANOVA was used to determine statistical difference between treatment 
groups, where p < 0.05 was considered statistically significant. 
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Chapter Three 
The Telomerase Template Antagonist GRN163L Alters MDA-MB-231 Breast 
Cancer Cell Growth and Structure, and Augments the Effects of Paclitaxel  
The work presented in this chapter has been prepared for submission as “The Telomerase 
Template Antagonist GRN163L Alters MDA-MB-231 Breast Cancer Cell Structure and 
Augments the Effects of Paclitaxel” by Erin M. Goldblatt, Erin Gentry, Sergei Gryaznov, 
and Brittney-Shea Herbert.  
 
Abstract 
Telomeres are repetitive (TTAGGG)n DNA sequences found at the end of 
chromosomes that protect the ends from recombination, end to end fusions, and 
recognition as damaged DNA. Telomerase activity can be detected in 85-90% of human 
tumors, which stabilizes telomeres and prevents apoptosis or senescence. The objective 
of the present study was to elucidate the mechanisms underlying the rapid response to the 
telomerase template antagonist GRN163L in MDA-MB-231 breast cancer cells and 
whether GRN163L could be used in mechanism-based combination therapy. In vitro, 
GRN163L induces altered cell morphology and reduced growth rates without a 
significant effect on breast cancer cell viability within the first 14 days. Combination 
treatment of GRN163L and paclitaxel significantly decreased viability compared to 
paclitaxel alone or a mismatch oligonucleotide plus paclitaxel. Additionally, in vivo 
MDA-MB-231 tumor formation was significantly inhibited with GRN163L and 
paclitaxel, and this combination significantly reduced invasion of MDA-MB-231 cells in 
vitro. These data support a rationale for potentially combining GRN163L with paclitaxel 
for the treatment of breast cancer in the clinical setting.  
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Introduction 
Breast cancer is one of the most common malignancies among women. Typically, 
after surgical removal of the tumor mass, breast cancer patients are treated with radiation 
and/or chemotherapeutic drugs that are highly toxic and lack selectivity, and resistance 
often develops quickly. Additionally, approximately 20% of women with a history of 
early breast cancer will develop metastatic disease (Stevanovic et al. 2006). Metastatic 
tumors are responsible for approximately 90% of cancer related deaths, making the 
development of new treatments that inhibit metastasis highly important in cancer therapy. 
Current therapies are aimed to prolong survival, control symptoms, and maintain the 
quality of life for breast cancer patients (Orlando et al. 2007, Barni and Mandalà 2005).  
Telomerase activity can be detected in 85-90% of human tumors, but not in 
normal somatic cells, making telomerase an attractive target for cancer therapy (Kim et 
al. 1994). Telomerase inhibition results in the erosion of telomeric DNA, genomic 
instability, and eventually to apoptosis or senescence (Herbert et al. 2005, Gellert et al. 
2006, Shay 2003). Previous studies from our laboratory have shown that in vitro, the 
telomerase template antagonist GRN163L reduces colony formation ability and 
replicative capacity of breast cancer cells within two weeks. In addition, using in vivo 
human xenograft models in mice, GRN163L reduces human breast tumor volume and 
metastases within 30 days (Hochreiter et al. 2006). This reduction in breast cancer 
metastasis may be explained by GRN163L inhibiting tumor cells migration, adherence, 
or growth at distant sites (Hochreiter et al. 2006, Jackson et al. 2007). Previous reports 
have demonstrated that inhibiting telomerase activity alone or in combination with 
current therapeutic techniques can inhibit tumor cell growth in vitro (Ward and Autexier 
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2005, Cerone et al. 2006a, Gomez-Millan et al. 2007). These studies demonstrated that 
the augmented combination effect with telomerase inhibitors is through telomere 
dysfunction.  
Microtubules are the major components of the cytoskeleton, and are vital for the 
maintenance of cell shape, signaling, and proliferation, making them an important target 
for anti-cancer drugs (Jordan and Wilson 2006, Tommasi et al. 2007). Paclitaxel is one of 
the most extensively utilized anti-cancer agents, with clinical efficacy in a wide range of 
cancers (Wang et al. 2000, Barni and Mandalà 2005). Paclitaxel acts to stabilize 
microtubules, thus inhibiting cell proliferation at the metaphase/anaphase boundary 
(Rowinsky 1997, Jordan et al. 1996, Mo et al. 2003). However, the success of paclitaxel 
in the clinical setting can often be tempered by drug resistance, which severely limits the 
effectiveness of chemotherapy. Although the exact mechanisms remain unclear, this 
phenomenon is considered to be mediated by altered drug uptake, variations in tubulin 
structure, and evasion of apoptotic pathways (Fojo and Menefee 2007). 
During cancer progression, cells can develop the ability to become invasive, 
which allows access to transportation through blood and lymphatic vessels (Barkan et al. 
2008, Azios et al. 2007, Acconcia et al. 2006). Under normal conditions, cells require 
attachment to a solid surface before they can grow. Adhesion is mediated by the secretion 
of molecules found in the extracellular matrix (ECM), such as collagen, laminin, and 
fibronectin (Barkan et al. 2008). Integrins are cell-surface matrix receptors that act to 
sense whether or not cells are attached to these matrix proteins. Integrins cluster to form 
focal adhesions, which affect the organization of the cytoskeleton and activate 
intracellular signaling pathways, including signals for proliferation, survival, and 
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migration (Parsons 2003, Cary and Guan 1999). Migration occurs through a continuing 
cycle of disrupting focal adhesions, extension of membrane protrusions at the advancing 
edge and contraction of the trailing ends of the cell, and the formation of new focal 
adhesions (Acconcia et al. 2006).  The formation of focal adhesions helps in the 
organization of the cytoskeleton and activates intracellular signaling pathways, including 
signals for proliferation, survival, and migration (Parsons 2003, Cary and Guan 1999, 
Barkan et al. 2008). 
Focal adhesion kinase (FAK) and Pyk2 are two important proteins associated with 
cellular morphology, growth, proliferation, and migration. The exact roles of Pyk2 and 
FAK in cancer remain unclear, and published reports suggest possible antagonistic 
cellular functions for Pyk2 and FAK (Gelman 2003). Induction of Pyk2 expression has 
been shown to inhibit cell cycle progression and stimulates cell migration, while FAK 
expression can stimulate cell proliferation. Suppression of adhesion-induced FAK 
activation has been shown to inhibit the migration and invasion of cancer cells, possibly 
due to a reduction in protease secretion (Parsons 2003, Cary and Guan 1999, Schlaepfer 
et al. 2004, Barkan et al. 2008). Interestingly, Pyk2 is capable of compensating for some, 
but not all, FAK-regulated functions in FAK-knockout cells (Sieg et al. 2000, Gelman 
2003). 
Metastatic breast cancer is a highly heterogeneous disease; therefore the 
development of new therapeutic regimens is becoming exceedingly important. New 
treatment options have emerged with the introduction of novel agents, but success is still 
hindered by the development of resistance to therapy. The use of multiple agents in 
combination often results in therapeutic synergy, which may be able to overcome drug 
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resistance in a large number of cancers. However, current combination therapies rely on 
methods that are toxic to both normal and cancer cells. GRN163L, a telomerase template 
antagonist currently in clinical trials, has previously been shown to be specific to cancer 
cells, with little effect on normal cells (Hochreiter et al. 2006), making this an appealing 
compound to use in combination therapies.  
The overall goal of this present study was to determine the cellular response to 
GRN163L to understand how this compound may augment breast cancer therapy. 
GRN163L was found to induce a rapid change in cellular architecture, leading to the 
hypothesis that GRN163L can augment the effects of the microtubule stabilizer paclitaxel 
in reducing the cell growth of breast cancer cells. The combined treatment of nM/sub-nM 
concentrations of GRN163L and paclitaxel resulted in a significant synergistic 
combination index in reducing the cellular proliferation and invasive potential of MDA-
MB-231 breast cancer cells.  Furthermore, this reduction in MDA-MB-231 breast cancer 
cell growth by combination treatment was observed in vivo, indicating a potential use for 
GRN163L in adjuvant therapy for breast cancer. 
 
Results 
Treatment with a single dose of GRN163L inhibits telomerase activity for six days in 
MDA-MB-231 breast cancer cells 
To confirm GRN163L as an effective telomerase inhibitors in breast cancer cell 
lines, MDA-MB-231 cells were treated with 2.5 μM GRN163L or mismatch (MM) 
oligonucleotide and collected after 1-6 days to determine the length of inhibition after a 
single treatment. As shown in Figure 3.1, GRN163L effectively inhibited telomerase  
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Figure 3.1. GRN163L effectively inhibits telomerase activity over six days after a 
single treatment. MDA-MB-231 breast cancer cells were treated with 2.5 μM GRN163L 
or mismatch oligonucleotides and collected after 1-6 days to determine the length of 
inhibition after a single treatment. Telomerase activity was analyzed using the 
Telomerase Repeat Amplification Assay (TRAP). Results shown are the telomerase 
products depicted as a ladder. Relative telomerase activity was calculated as the ratio of 
telomerase products (ladder) intensity to the intensity of the internal control (IC) band 
and normalized to the untreated (media only) sample. A positive control cell extract 
(TRAPeze® Telomerase Detection kit) and NP-40 lysis buffer (LB) were used as a 
positive and negative control, respectively. UT= untreated sample; HI= heat inactivated 
control samples; MM= mismatch control treated samples.  
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activity in MDA-MB-231 cells through six days after a single treatment. The mismatch 
(MM) control oligonucleotide had no significant effect on telomerase activity. 
 
Treatment with GRN163L alters the morphology of breast cancer cells 
Previous in vivo experiments have demonstrated a reduction in metastasis within 
30 days exposure to GRN163L (Hochreiter et al. 2006). This may be due to an inhibition 
of breast cancer cell migration and/or growth at distant sites. To test the cellular 
responses to GRN163L, MDA-MB-231 breast cancer cells were treated with 19.5 nM- 
2.5 μM GRN163L or 10 μM mismatch oligonucleotides, and the cellular morphology 
was monitored daily. Non-tumorigenic MCF10A cells were used to determine whether 
the response to GRN163L was cancer cell specific. In addition, MDA087 immortalized 
breast fibroblasts, which utilize the alternative lengthening of telomeres (ALT) pathway 
and do not express telomerase activity, were also tested to determine if the cellular 
responses to GRN163L required telomerase. As shown in Figure 3.2, the morphology of 
MDA-MB-231 cells was altered by treatment with GRN163L, resulting in a rounding-up 
effect on adherent cells as well the extension of fillipodia-like structures. This effect was 
observed with 0.3125-2.5 μM GRN163L, but treatment with lower doses did not result in 
altered morphology. In contrast, normal mammary epithelial cells did not demonstrate a 
morphological response to treatment with GRN163L. Interestingly, MDA087 breast 
cancer cells utilizing the ALT pathway also demonstrated a morphological response to 
treatment with GRN163L similar to that observed in MDA-MB-231 cells. This finding 
indicates that the effect of this telomerase template antagonist may be independent of 
telomerase activity. Additionally, the morphological response to GRN163L was tested in  
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Figure 3.2. Morphology changes in response to treatment with GRN163L. 5x104 
MDA-MB-231 breast cancer cells were plated in 6-well dishes with 2.5 μM GRN163L or 
mismatch (MM) oligonucleotide and monitored every 12 hrs for alterations in 
morphology using a light microscope. Within 24 hours, treatment with GRN163L 
induced morphologic changes in MDA-MB-231 breast cancer cells and MDA087 
telomerase-negative, immortalized breast fibroblasts with no effect in non-tumorigenic 
MCF10A cells. Cells are shown after 72 hours of treatment. Arrows point to rounded 
cells, arrowheads point to fillipodia-like structures. 
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a wide array of breast cancer cell lines, including luminal and HER2+ breast cancer cells. 
All cell lines tested demonstrated a cell-type specific change in morphology in response 
to GRN163L (data not shown). Interestingly, the effects of GRN163L on cell adhesion 
and architecture is reversible with the addition of ECM proteins to cell culture dishes 
(Goldblatt et al. unpublished observations; Jackson et al. 2007). This reversibility 
indicates that GRN163L may be interfering with the ability of breast cancer cells to make 
or secrete ECM proteins, or the binding of integrins to the ECM. 
 
GRN163L significantly inhibits cell proliferation in MDA-MB-231 cells  
To determine the effect of GRN163L on cell growth, MDA-MB-231 cells were 
plated onto tissue culture dishes in triplicate. As shown in Figure 3.3a, treatment with 
GRN163L dramatically inhibited breast cancer cell growth over time. Treatment with 
mismatch oligonucleotide had no effect on cell growth, indicating that the effect on cell 
growth is not related to the use of lipidated oligonucleotides but is intrinsic to the 
telomerase template antagonist. The total population doublings per week were calculated 
to determine the rate of growth inhibition. As shown in Figure 3.3b, the average time for 
one population doubling increased from 1.5 days in untreated cells, to 4.25 days in cells 
treated with GRN163L (p = 4.34 x 10-7). As expected, the mismatch oligonucleotide 
again had no effect on population doubling rate compared to untreated cells (p = 0.22). 
To further understand the growth inhibition induced by GRN163L, cell 
proliferation was measured using a commercial BrdU incorporation assay. MDA-MB-
231 cells were treated with 0.5-2.5 μM GRN163L or 2.5 μM mismatch oligonucleotide 
for 72 hours. These doses all induced a morphological response to GRN163L and 
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Figure 3.3. Effect of GRN163L on cell growth. (A) 5x104 MDA-MB-231 cells were 
plated in 6-well plates in triplicate. Cells were treated with 2.5 μM GRN163L or 
mismatch (MM) oligonucleotide, replenishing the drug every third day. After 7 days, 
cells were collected and counted to determine population doublings. Each sample was 
counted in triplicate. Triplicate samples were combined before replating to avoid 
selection for resistant cells. (B) Average time for one population doubling was 
determined for MDA-MB-231 cells in response to GRN163L or mismatch (MM) 
oligonucleotides. GRN163L significantly increases the average doubling time of MDA-
MB-231 cells (p = 4.34 x 10-7). Mismatch oligonucleotide has no effect on doubling rate 
(p = 0.22). 
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reduced growth of MDA-MB-231 cells (Figure 3.3). Results demonstrate that cell 
proliferation is significantly inhibited even at the 0.5 μM dose of GRN163L (Figure 3.4; 
p < 0.005) and progressively decreases at higher doses. The mismatch control did not 
have a significant effect on BrdU incorporation (p > 0.05). Taken together with the 
growth inhibition, the decrease in BrdU incorporation indicates that the growth inhibition 
induced by GRN163L may be due to difficulty progressing through the DNA synthesis 
and cell division phases of the cell cycle. The reduction in proliferation as measured by 
BrdU incorporation correlates with the increase in doubling time after treatment with 
GRN163L. After 72 hours, there are 75% fewer cells in the GRN163L treated group 
versus controls (Figure 3.3) and an 80% reduction in BrdU incorporation (Figure 3.4). 
The results of these assays together could be explained through two possible scenarios. 
GRN163L alters cell morphology and adhesive ability (Figure 3.2). The altered 
morphology could interfere with proper cell division, and therefore lessen the number of 
cells undergoing DNA replication (explaining the decrease in BrdU incorporation). 
Alternatively, if GRN163L inhibits DNA synthesis, cell proliferation would decrease and 
population doubling time would increase.  
 
GRN163L significantly inhibits colony formation ability of breast cancer cells 
The plating efficiency (PE) of MDA-MB-231 cells after exposure to 1 μM 
GRN163L for ~5 days was studied to determine whether the change in doubling time is 
associated with an overall decrease in replicative potential and survival capacity. 
Treatment with GRN163L resulted in a significant decrease in PE, from 0.876 ± 0.086 in 
untreated cells to 0.216 ± 0.062 in cells treated with GRN163L (p = 0.009). The 
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Figure 3.4. GRN163L inhibits cell proliferation within 72 hours. MDA-MB-231 cells 
were grown in 96-well plates with 0.5, 1, or 2.5 μM GRN163L or 2.5 μM mismatch 
oligonucleotides for 72 hours. 10 μM BrdU was added to culture media 12-18 hours prior 
to assay. BrdU incorporation was measured at 405 nm with a reference wavelength at 490 
nanometers. UT = untreated (media only), MM = mismatch control treated. ** p < 0.005.  
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mismatch control oligonucleotide did not result in significant reduction in PE (Figure 3.5; 
p = 0.08). This decrease in proliferative potential occurs prior to bulk telomere 
shortening, indicating a rapid effect on the proliferative ability of MDA-MB-231 cells. 
This result has previously been seen with other breast cancer cell lines with treatment 
times of 2-3 passages (≤ 2 weeks) (Hochreiter et al. 2006, Gellert et al. 2006). 
 
GRN163L does not induce apoptosis or reduce cell viability in MDA-MB-231 cells within 
the first two weeks 
One explanation for the reduction in cell growth and longer population doubling 
time in short-term GRN163L-treated MDA-MB-231 cells is the induction of cell death, 
particularly apoptosis. To test for the induction of apoptosis, MDA-MB-231 cells were 
treated with 2.5 μM GRN163L or mismatch oligonucleotides for 72 hours and analyzed 
for DNA fragmentation. To assess the induction of apoptosis, the amount of histone-
associated DNA released into the cytoplasmic fraction of cell lysates was measured using 
the Cell Death Detection ELISA. Doxorubicin was used a positive control, as this 
chemotherapy drug is known to induce apoptosis. As shown in Figure 3.6, treatment with 
GRN163L did not induce cell death within 72 hrs. While GRN163L did not induce rapid 
cell death, there was an obvious reduction in cell growth that may be due to a reduction in 
cell viability. To determine the long term effects of GRN163L on cell viability, MDA-
MB-231 cells were treated with 2.5 μM GRN163L or mismatch oligonculeotides, and 
collected and counted via the Trypan blue exclusion assay daily for fourteen days. 
Although there is a decrease in cell number, the remaining cells did not demonstrate  
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Figure 3.5. GRN163L reduces proliferative potential of MDA-MB-231 cells. Plating 
efficiency was determined by treating MDA-MB-231 cells with 1 μM GRN163L or 
control mismatch oligonucleotide (MM) for ~5 days prior to seeding at clonal density. 
Plating efficiency (PE) was calculated by dividing the average number of colonies by the 
number of cells initially plated. The PE decreased from 0.876 ± 0.086 in untreated (media 
only) cells to 0.216 ± 0.062 in cells treated with GRN163L (** p=0.009). The mismatch 
control oligonucleotide did not result in significant reduction in PE (p = 0.08). Data is the 
average of multiple experiments.  
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Figure 3.6. GRN163L does not induce apoptotic cell death within 72 hrs of 
treatment. 5x105 MDA-MB-231 cells were plated in 10cm2 dishes with 2.5 μM 
GRN163L or mismatch (MM) oligonucleotide. 5 μM doxorubicin was used as a positive 
control. Cells were incubated for 72 hours prior to collection and use in the Cell Death 
ELISA (Roche). The absorbance was read at 405 nanometers with a reference 
wavelength of 490 nanometers.  Results are representative of two experiments. UT= 
untreated (media only) control cells; *** p < 0.0005. 
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significantly decreased viability (Table 3.1). These results taken together indicate that the 
growth inhibition seen in MDA-MB-231 breast cancer cells for the first two weeks of 
treatment with GRN163L is independent of a reduction in viability or an induction of 
apoptosis. 
 
GRN163L disrupts focal adhesion formation and actin filament organization 
The altered morphology and adhesion capacity observed in response to treatment 
with GRN163L suggests a change in the cell membrane. To test the effect of GRN163L 
on the cell structure, the actin filaments and focal adhesions were microscopically 
examined to determine whether this telomerase template antagonist can disrupt structural 
organization of breast cancer cells. The regulation of focal adhesion and actin filament 
organization is important for cell migration (Sieg et al. 1999). MDA-MB-231 cells were 
treated with 2.5 μM GRN163L or mismatch oligonucleotides in chamber slides, and 
grown for 72 hours, prior to fixing and staining. Results are shown in Figure 3.7. 
Untreated cells and mismatch control treated cells displayed well-organized actin 
filaments (phalloidin staining, in red) in long, parallel projections equally distributed 
throughout the cell, possibly helping to maintain cell shape (Sieg et al. 1999). However, 
in GRN163L treated cells, the actin fiber organization was observed primarily along the 
edges of the cell rather than in filaments throughout the cell. This dense accumulation 
around the perimeter of the cell indicates a reduction in stress fiber contractility (Sieg et 
al. 1999). Additionally, cells treated with GRN163L display fillipodia-like structures 
Furthermore, under normal physiological conditions, cells form focal adhesions in 
multiple places along the cell membrane, primarily located at the ends of actin 
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Table 3.1. GRN163L does not significantly inhibit MDA-MB-231 cell viability.  
 
 
 
 Untreated GRN163L Mismatch 
Day 1 92.18 86.65 89.17 
Day 2 90.00 85.43 85.45 
Day 3 90.61 88.93 91.63 
Day 4 92.25 84.55 94.21 
Day 5 95.83 85.71 94.62 
Day 6 94.10 87.10 92.59 
Day 7 96.93 83.78 97.26 
Day 10 95.24 87.50 96.61 
Day 14* 85.37 85.15 88.44 
 
 
MDA-MB-231 cells were treated with 2.5 μM GRN163L or mismatch oligonucleotides 
every third day. Cell viability was measured daily using the Trypan blue exclusion assay 
and reported in percent values. Cell viability decreased by 10-15% after treatment with 
GRN163L. Mismatch oligonucleotide had no effect on viability. * After 14 days, cells 
were overly confluent, resulting in decreased viability of untreated (media only) and 
mismatch control cells. 
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filaments (Sieg et al. 1999). As shown in Figure 3.7, untreated and mismatch control 
treated cells demonstrated this pattern of focal adhesion formation (vinculin staining, in 
green). However, GRN163L treated cells displayed punctate staining concentrated 
around the nuclei of the cells with little staining throughout the remaining cell membrane. 
This disruption of regular adhesion proteins/elements could help to explain the rounding-
up/detachment or cell spreading disruption effects observed in breast cancer cells in 
response to GRN163L. 
 
GRN163L alters the expression of proteins involved in cellular structure and function 
The morphology and structural changes induced by treatment with GRN163L 
indicates that the expression of proteins involved in signaling cellular attachment and 
intracellular organization may be altered. In an effort to understand the mechanism 
underlying the response to treatment with GRN163L, the protein levels of β- and γ-
tubulin were measured by Western immunoblotting to determine changes in two of the 
main components of microtubules. Additionally, FAK and Pyk2 were measured, as these 
proteins play a role in microtubule organization, cell spreading, growth, and proliferation 
(Parsons 2003, Cary and Guan 1999, Barkan et al. 2008, Zhao et al. 2000, Lipinski 2003). 
Changes in any of these proteins could result in the changes in MDA-MB-231 cell 
morphology and growth. As shown in Figure 3.8, the levels of β- and γ-tubulin, as well as 
basal FAK, did not significantly shift in response to treatment with GRN163L. The 
expression of Pyk2, however, increased in a cyclical fashion after 12 and 72 hours 
treatment with GRN163L.  
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Figure 3.7. Effects of GRN163L on focal adhesion formation and actin filament 
organization. MDA-MB-231 cells were plated on chamber slides with 2.5 μM 
GRN163L or mismatch oligonucleotides for 72 hours. Cells were fixed and stained with 
phalloidin (actin filaments) or vinculin (focal adhesions). GRN163L disrupts cell 
adhesion as evidenced by punctate vinculin staining rather than diffuse staining seen in 
untreated (media only) and mismatch control treated samples. GRN163L also disrupts 
cell structure, as seen by altered actin filament organization.  Panels are representative 
cells from a larger field (insets). Scale bars (50 μm) depicted in top left panel represents 
scale for all panels and insets. Arrow heads point to rounded up cells with punctuate 
vinculin staining. 
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Figure 3.8. GRN163L effects the expression of signaling pathway proteins involved 
in cellular structure and function. MDA-MB-231 cells were treated with 2.5 µM 
GRN163L or mismatch oligonucleotides for the depicted times. Western immunoblotting 
for the indicated adhesion and morphology proteins was performed (A). Densitometry 
levels were determined by comparing intensity of FAK, Pyk2, γ-tubulin, and β-tubulin to 
GAPDH and relative intensity levels for each sample were plotted and normalized to 
untreated (media only) samples (B). Untreated and mismatch (MM) control treated cells 
were analyzed after 72 hours.  
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proliferation. Speculatively, the upregulation of Pyk2, a protein involved in reshaping 
cellular architecture, may be induced to aid the cell in reshaping its actin filaments. 
Restructuring the actin filaments into a more regular pattern could potentially allow the 
cell to continue replicating in a normal fashion.  
 
GRN163L synergistically enhances the effects of paclitaxel on inhibiting cell 
proliferation in breast cancer cells 
The disruption of actin structures in MDA-MB-231 cells by GRN163L suggests 
that GRN163L may work synergistically with paclitaxel to inhibit breast cancer cell 
growth. To test the effect of combination therapy on cell growth, cells were plated with 
0.005-1.25 μM GRN163L either alone or with 0.5-12.5 nM paclitaxel for five days. This 
range of doses encompasses treatments that do not induce morphological responses, as 
well as those that are known to affect cell morphology and growth. Cells were collected 
and counted to determine the effect of individual or combination therapy on cell growth. 
MDA-MB-231 cells displayed a dose-dependent response to both paclitaxel and 
GRN163L in terms of cell growth inhibition (Figure 3.9). The mismatch control 
oligonucleotide did not exhibit significant inhibitory effects on cell growth. On the other 
hand, the combination of GRN163L and paclitaxel resulted in a significant shift in the 
growth inhibition curve compared to either agent alone (Figure 3.9, upper panel). Low 
doses of GRN163L were used to rule out any possible cytotoxicity induced by the lipid-
modified oligonucleotide. The synergistic effect of combination treatment was true even 
at low nM doses of GRN163L, where telomerase is can still be inhibited, albeit at a lower 
level. Importantly, the mismatch control did not alter the growth inhibition effects of 
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Figure 3.9. GRN163L synergistically augments the effects of paclitaxel in MDA-MB-
231 breast cancer cells.  MDA-MB-231 cells were treated with 1:2 serial dilutions of 
GRN163L or a mismatch oligonucleotide alone (MM), paclitaxel alone, or the 
combination of GRN163L/MM with paclitaxel at a 1:10 ratio. Cells were collected after 
five days to determine cell number (and viability). Percent growth inhibition was plotted 
versus concentration for each treatment group (top panel). Calcusyn software (Biosoft, 
Cambridge UK) was used to ascertain the combination index (CI) value for each 
combination ratio (Dose) to determine whether combination treatments have an additive 
or synergistic effect (lower panel; ±SD). A CI value of CI <1.0 denotes synergistic 
interaction (more than additive), a CI of 1.0 demonstrates summation (additive), and a CI 
>1.0 indicates antagonistic interaction (less than additive). 
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paclitaxel. The combination index (CI) as developed by Chou and Talalay (Chou and  
Talalay 1984) was determined for the dual therapy to determine whether combination 
therapy was synergistic (CI < 1.0), additive (CI = 1.0), or antagonistic (CI > 1.0). As 
shown in Figure 3.9 (lower panel), GRN163L acted synergistically with paclitaxel to 
inhibit cell growth of MDA-MB-231 cells at all combination doses tested.   
 
GRN163L has no effect on the growth inhibition induced by paclitaxel in non-
tumorigenic MCF10A cells   
To determine whether the effects of lipid-conjugated telomerase template 
antagonists and paclitaxel on cancer cell growth could also be observed in non-
tumorigenic breast epithelial cells MCF10A cells were treated in the same manner as in 
the experiments with the MDA-MB-231 cells. As shown in Figure 3.10, GRN163L and 
the mismatch oligonucleotide control alone had no significant effect on the proliferation 
of MCF10A cells. Paclitaxel alone did inhibit cell growth at high doses, which would be 
expected after treatment with this mitotic inhibitor. The addition of GRN163L or 
mismatch oligonucleotide, however, had no significant effect on cell growth inhibition 
induced by paclitaxel. 
 
The combination of GRN163L and paclitaxel significantly inhibit tumor growth in vivo 
To test that the effects of combining GRN163L and paclitaxel can be seen in vivo 
as well as in vitro, the combination treatment was examined on the growth of orthotopic 
MDA-MB-231 tumors. MDA-MB-231 breast cancer cells were injected into the 
mammary fat pads of 6- to 8-weekold mice. Mice were treated with 30 mg/kg GRN163L 
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Figure 3.10. GRN163L does not change the effect of paclitaxel in MCF10A cells. 
MCF10A cells were treated with 1:2 serial dilutions of GRN163L or a mismatch 
oligonucleotide alone (MM), paclitaxel alone, or the combination of GRN163L/MM with 
paclitaxel at a 1:10 ratio (paclitaxel: GRN163L/MM). Cells were collected after five days 
to determine cell number (and viability). Percent growth inhibition was plotted versus 
concentration for each treatment group (top panel).  
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three times weekly and 15 mg/kg paclitaxel once weekly intraperitoneally (IP). Figure 
3.11 depicts the overall tumor growth over the course of the experiment. All groups 
displayed an initial lag in tumor growth followed by progressive disease. The 
combination of GRN163L + paclitaxel, however, did significantly decrease tumor 
volume over PBS control treated animals (p = 0.0072). GRN163L was well tolerated by 
the mice, and the animals did not show any health or behavioral problems. At the end of 
this experiment, mice treated with GRN163L and paclitaxel displayed better survival 
rates than control animals (93% survival vs. 80% in control animals) or animals treated 
with either drug alone (81% in GRN163L treated animals, 86% in paclitaxel treated 
animals) due to mice experiencing excess tumor burden. 
 
The combination of GRN163L and paclitaxel significantly inhibits cell invasion over 
either drug alone  
 GRN163L has been shown to inhibit cell migration/invasion and metastasis 
(Hochreiter et al. 2006, Jackson et al. 2007). The data presented in this dissertation, 
however, demonstrates an effect of GRN163L on cell growth at a much lower 
concentrations than previous studies (nM vs. µM), indicating that these lower doses may 
also inhibit the invasive potential of breast cancer cells. To test this theory, the ability of 
MDA-MB-231 cells to migrate through an artificial membrane after treatment with 
GRN163L or mismatch oligonucleotides was determined. MDA-MB-231 breast cancer 
cells were treated with 0.156-0.3125 μM GRN163L or mismatch oligonucleotides alone 
or in combination with 16-31nM paclitaxel for five days. Following treatment, cells were 
plated into matrigel-coated invasion chambers in serum free media for 24 hours.  The 
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Figure 3.11. Efficacy of GRN163L in combination with paclitaxel in vivo.  Tumor 
growth rate in mice treated with PBS control, GRN163L alone (30 mg/kg), paclitaxel 
alone (15 mg/kg), or the combination of GRN163L and paclitaxel is shown (n=30 tumors 
per group). Data are presented as mean tumor volume ± SE. Statistical differences were 
calculated using the Student’s t-test (Microsoft excel). There was no statistical difference 
in the average tumor size between UT and GRN163L (p = 0.16) or paclitaxel (p = 0.07). 
There was also no significant different between GRN163L and paclitaxel (p = 0.41), or 
either drug alone versus the combination of both drugs (p = 0.13 and p = 0.15, 
respectively). There was, however, a significant difference in the average tumor size of 
control mice versus mice treated with GRN163L ± paclitaxel (** p = 0.014). 
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bottom well of the invasion chamber contained media with serum as a chemoattractant to 
stimulate cell migration. As shown in Figure 3.9 (page 72), these doses of GRN163L 
inhibit cell growth by 40-50%, and paclitaxel inhibited cell growth by approximately 
80%. The combination of GRN163L and paclitaxel at these doses inhibited cell growth 
by 100%. As shown in Figure 3.3 (page 60), the doubling time of MDA-MB-231 cells 
increases to 4.25 days after treatment with GRN163L. Therefore, measuring growth after 
five days of treatment with GRN163L and paclitaxel takes into account the growth delay 
induced by GRN163L alone when determining the effect of combination therapy. Equal 
numbers of control and treated cells were assayed for invasive potential. As shown in 
Figure 3.12, GRN163L and paclitaxel alone inhibit cell invasion compared to control 
cells (p = 0.046 and 0.006 respectively), whereas the mismatch oligonucleotide had no 
effect (p = 0.47). The combination of GRN163L and paclitaxel significantly decreased 
invasion compared to either drug alone (p = 0.002 vs. GRN163L alone; p = 0.017 vs. 
paclitaxel alone). The combination of mismatch oligonucleotide and paclitaxel had no 
significant effect on the inhibition of invasion induced by paclitaxel alone (p = 0.23). 
 
Discussion 
The data presented here reinforces the use of GRN163L in the treatment of 
cancer, particularly breast cancer. This compound is known to be an effective telomerase 
inhibitor; the mechanisms underlying response were, however, unclear. As shown in this 
chapter, GRN163L likely disrupts normal focal adhesion formation and actin filament 
organization, thus disrupting normal cell adhesion and structure. This response 
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Figure 3.12. The combination of GRN163L and paclitaxel significantly inhibits 
invasive potential of breast cancer cells in vitro. MDA-MB-231 cells were treated with 
0.156-0.3125 µM GRN163L or mismatch oligonucleotides with or without 15.6-31 nM 
paclitaxel for five days prior to measuring invasive ability. Cells were plated on matrigel-
coated invasion chambers for 24 hours. Culture media containing 10% cosmic calf serum 
was used as a chemoattractant. BJ fibroblasts were used as a negative control (data not 
shown). Results are the average of four independent experiments. * = significantly 
different from untreated (media only) controls (p < 0.05); ** = significantly different 
from untreated controls and paclitaxel treatment (p < 0.05). Invasion was completely 
inhibited with 31 nM paclitaxel, and the addition of GRN163L or mismatch 
oligonucleotides had no further effect (data not shown). 
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significantly delays the growth of MDA-MB-231 cells without a reduction in cell 
viability or the induction of apoptosis. Importantly, this effect of GRN163L sensitized 
breast cancer cells to paclitaxel, an important chemotherapeutic used in the treatment of 
breast cancer. Additionally, the combination of GRN163L and paclitaxel significantly 
decreased tumor volume over PBS control treated animals (p = 0.014) and increased 
survival rates (data not shown). However, this effect on tumor growth was not significant 
when compared to paclitaxel or GRN163L alone (p > 0.05).  Although the effect of 
combination therapy on the rate or incidence of metastasis was not tested in vivo, in vitro 
invasion assay results suggest that GRN163L plus paclitaxel significantly reduce the 
invasive potential of MDA-MB-231 cells. 
Microtubules are the major components of the cytoskeleton, consisting of long, 
tube-shaped protein polymers. Microtubules are vital for the maintenance of cell shape, 
intracellular transport, cell signaling, and cell division, making them an important target 
for anti-cancer drugs (Jordan and Wilson 2006, Tommasi et al. 2007). Paclitaxel is one of 
the most extensively utilized anti-cancer agents that binds to microtubules and increases 
polymerization, inhibiting cell proliferation at the metaphase/anaphase boundary (Wang 
et al. 2000, Barni and Mandalà 2005, Rowinsky 1997, Jordan et al. 1996, Mo et al. 2003). 
Despite the clinical efficacy of the taxanes, there are tissue specificity and drug resistance 
issues associated with this class of chemotherapy drugs.  Mechanisms underlying 
resistance remain unclear, as does the explanation as to why paclitaxel is an effective 
therapy for certain types of cancers (Jordan and Wilson 2006, Tommasi et al. 2007).  This 
also indicates the need for new forms of therapy that can target resistant cells. 
Additionally, the toxicity of chemotherapeutic drugs indicates the need for new 
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combinations of therapies that will shorten treatment times to reduce the negative side 
effects associated with treatment.  
The results presented herein indicate that the reduction in metastasis seen 
previously in response to GRN163L (Hochreiter et al. 2006, Jackson et al. 2007) could be  
due to a loss of proliferative potential of breast cancer cells, as demonstrated by a 
reduction in growth rates and DNA synthesis. While the response to GRN163L does not 
induce rapid cell death via apoptosis or decreased cell viability over two weeks, this does 
not rule out the fact that loss of a sentinel, critically short telomere(s) may affect cell 
survival and trigger alternate forms of growth arrest or cell death, such as autophagy, as 
shown by the recent report on telomere-targeting oligonucleotides (Aoki et al. 2007). As 
discussed in Chapter Two, it is also possible that early-stage telomere dysfunction 
induced by GRN163L induces mitotic catastrophe, which would result in failure of cell 
cycle arrest before or at mitosis due to abnormal spindle formation (Eom et al 2005, 
Castedo et al. 2004).   
 Under normal conditions, cells require attachment to a solid surface before they 
can grow. Adhesion is mediated by the secretion of molecules found in the extracellular 
matrix (ECM), such as collagen, laminin, and fibronectin (Barkan et al. 2008). The 
formation of focal adhesions helps in the organization of the cytoskeleton and activates 
intracellular signaling pathways, including signals for proliferation, survival, and 
migration (Parsons 2003, Cary and Guan 1999, Barkan et al. 2008). During cancer 
progression, cells develop the ability to become invasive, which allows for transportation 
through blood and lymphatic vessels (Barkan et al. 2008, Azios et al. 2007, Acconcia et 
al. 2006). Migration occurs through a continuing cycle of disrupting focal adhesions, 
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extension of membrane protrusions at the advancing edge and contraction of the trailing 
ends of the cell, and the formation of new focal adhesions (Acconcia et al. 2006). The 
response to GRN163L may disrupt this process, thus inhibiting the metastatic potential of 
migrating cancer cells. Indeed, the cytoskeleton plays a major role in the transition from a 
dormant state to a state of migration, with quiescent cells maintaining a more rounded 
shape. Metastatic cells often have highly regular actin filaments, indicating a strong 
attachment to the ECM (Barkan et al. 2008). In addition to the effect on cell growth, we 
demonstrate that GRN163L has an effect on cell architecture, resulting in altered actin 
filament organization and focal adhesion formation. These changes could lead to a 
reduction in migratory potential of breast cancer cells, thus reducing metastatic disease. A 
reduction in migration after treatment with GRN163L has been demonstrated in lung 
cancer cells (Jackson et al. 2007), although the mechanisms underlying this effect remain 
to be elucidated. That study, however, used a higher dose of GRN163L to inhibit 
migration and invasion than the doses used in these experiments. The results shown in 
Figure 3.9 (page 72) suggest that the combination of GRN163L and paclitaxel allows an 
effective growth inhibition at low nanomolar doses of both drugs, which would lead to 
reduced toxicitiy in patients. 
The effect of telomerase inhibition in sensitizing cancer cells to chemotherapy 
drugs and irradiation (IR) is well documented, but has been tested by inducing massive 
telomere shortening prior to seeing sensitization, indicating a long lag time (Cerone et al. 
2006a, Djojosubroto et al. 2005, Gomez-Millan et al. 2007, Ward and Autexier 2005). 
The data presented here shows that telomerase template antagonists can significantly 
increase the sensitivity of breast cancer cells to paclitaxel within five days, without a 
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significant effect on non-tumorigenic cells. In addition, GRN163L plus paclitaxel 
resulted in reduced or delayed MDA-MB-231 tumor growth in vivo. The combination of 
GRN163L and paclitaxel may, therefore, be effective in the treatment of breast cancer. In 
addition, the effect of this combination on the invasive potential of breast cancer cells in 
vitro and metastasis in vivo would therefore be important for breast cancer patients. 
Interestingly, we did not see an inhibition of tumor growth in vivo after treatment with 
GRN163L or paclitaxel, alone or in combination. This is not an unprecedented result, as 
previously published reports have shown that the combination of docetaxel, another 
microtubule inhibitor, and parthenolide, an NF-κB inhibitor, did not significantly 
decrease tumor volume over either drug alone (Sweeney et al. 2005). Lung metastasis, 
however, was significantly inhibited by combination therapy. The results of the invasion 
assay presented here indicate that the combination of GRN163L and paclitaxel may, 
therefore, be effective in the treatment of metastatic disease.  
Telomerase inhibition has classically demonstrated a long lag phase before critical 
telomere shortening and cell growth inhibition (Hahn et al. 1999, Zhang et al. 1999, 
Herbert et al. 1999). The research presented here, however, shows a rapid response to 
GRN163L, with significant effects on MDA-MB-231 breast cancer cell growth and 
morphology within five days. Taking advantage of this rapid response by treating cells 
with GRN163L and paclitaxel resulted in a highly significant decrease in cell growth, 
indicating that shorter exposure times may be possible to reduce secondary effects of 
treatment with toxic therapeutics (IR, chemotherapy, or molecular targeted therapy). The 
effect of GRN163L on cell adhesion and morphology is reversible (data not shown, 
Jackson et al. 2007), with the return of telomerase activity, telomere elongation and 
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maintenance, and normal cell architecture. One concern with the use of telomerase 
inhibitors in the clinical setting is the effect on stem and progenitor cells found in highly 
replicative tissues. The rapid response to GRN163L and paclitaxel shown here indicates 
that it is reasonable to expect that quiescent stem cells will not be significantly affected 
by short courses of telomerase inhibition therapy (Wright et al. 1996, Forsyth et al. 2002, 
Shay and Wright 2002). These results further support the use of telomerase inhibitors in 
combination with other therapeutic regimens for the treatment of breast cancer. Taken 
together with previously published reports demonstrating that GRN163L inhibits primary 
breast cancer tumor growth in vivo (Hochreiter et al. 2006, Gomez-Millan et al. 2007), 
these results provide a rationale for the use of this drug in breast cancer clinical trials.  
Therefore, treatment with telomerase template antagonists in therapeutic regimens could 
have beneficial outcome not only on primary tumor growth due to the effects of telomere 
shortening, but also in therapeutic regimens for sensitization to therapy and prevention of 
recurrence.  
 
Materials and Methods 
Cell culture 
MDA-MB-231 and MDA-087 breast cancer cells and BJ fibroblasts (American 
Type Culture Collection) were cultured in DMEM media containing 10% cosmic calf 
serum (HyClone, Logan, UT).  Non-tumorigenic MCF10A cells were cultured in MEGM 
(Cascade Biologicals). All cells were cultured at 37°C and 5% CO2 and routinely checked 
for mycoplasma contamination. 
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Reagents 
The telomerase template antagonist used in this study is complementary to the 
telomerase RNA component (hTR) template region for telomerase (5'-
CUAACCCUAAC-3'). The lipid-modified N3'→P5' thio-phosphoramidate 
oligonucleotide (GRN163L, 5'-Palm-TAGGGTTAGACAA-NH2-3') and the 5' -
palmitoyl mismatch control oligonucleotide (5'-Palm-TAGGTGTAAGCAA-NH2-3'), 
was prepared as previously described (Herbert et al. 2005). Paclitaxel was purchased 
from Sigma Chemical Co. (St. Louis, MO) and dissolved as a 10 mM stock in dimethyl 
sulfoxide (DMSO).  
 
Telomerase activity assay 
Telomerase activity was measured using the polymerase chain reaction– based 
Telomeric Repeat Amplification Protocol (TRAP) as previously described (Chapter Two; 
Hochreiter et al. 2006, Wright et al. 1995). After primer extension with a Cy5 
fluorescently labeled telomerase template primer and polymerase chain reaction 
amplification, the TRAP reaction products were run on a 10% nondenaturing acrylamide 
gel. The gel was visualized, without drying, on a PhosphorImager using ImageQuant 
software (Molecular Dynamics, Sunnyvale, CA). Telomerase activity was demonstrated 
as a 6-bp telomerase-specific ladder above the 36-bp internal standard control band (IC). 
 
Cell Growth and Viability Assays 
In order to determine how treatment with telomerase template antagonists or 
trastuzumab affect cell growth and viability, 5x104 cells were plated with 2.5 μM 
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GRN163L or mismatch oligonucleotides in 12-well dishes. Cells were collected weekly 
and counted via a Beckman Coulter Counter to determine cell number. Triplicate samples 
were combined prior to replating to avoid selection of resistant cells. To determine the 
effects of immediate treatment on cell viability, 10 μl cell suspension was mixed with 10 
μl Trypan blue and counted via hemacytometer.  
 
BrdU assay 
Cell proliferation was measured using the 5'-Bromo-2'-deoxy-uridine Labeling 
and Detection Kit (Roche Applied Sciences, Indianapolis, IN) according to 
manufacturer’s instructions. Briefly, 2 x 104 MDA-MB-231 cells were plated in 96-well 
plates with 0.5, 1, or 2.5 μM GRN163L or 2.5 μM mismatch oligonucleotides for 72 
hours. 10 μM BrdU was added for 18 hours prior to determination of cell proliferation. 
Absorbance was read at 490 nm. Student’s t-test was performed using Microsoft Excel. 
 
Colony formation assays 
MDA-MB-231 cells were treated with 1 μM GRN163L for ~5 days prior to 
plating for colony formation assays. 2-6 x 102 cells were plated in 25cm2 flasks. Six 
25cm2 flasks were plated for each treatment group, and colonies allowed to grow for 12-
14 days without changing the media or adding any drugs prior to staining with 20% 
Giemsa. Colonies with more than 50 cells were counted to determine the survival fraction 
of each group. Plating efficiency (PE) was calculated by dividing the average number of 
colonies by the number of cells initially plated. Experiments were repeated at least in 
triplicate. Student’s t-test was performed using Microsoft Excel. 
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Cell death assay 
Cell death was measured using the Cell Death Detection ELISA from Roche 
(Roche Applied Sciences, Indianapolis, IN) according to manufacturer’s instructions. 
Briefly, MDA-MB-231 cells were treated with 2.5 μM GRN163L or mismatch 
oligonucleotides for 72 hours. 5 μM doxorubicin (Sigma Chemical Co., St. Louis, MO) 
was used as a positive control for the induction of apoptosis. Student’s t-test was 
performed using Microsoft Excel. 
 
Focal adhesion and actin filament immunofluorescence 
Staining for focal adhesion formation and actin filament organization was done 
using the Actin Cytoskeleton and Focal Adhesion Staining Kit from Chemicon 
International (Temecula, CA) as per manufacturer’s protocol. Briefly, 5 x 104 MDA-MB-
231 cells were plated in chamber slides and grown for 72 hours. Cells were fixed in 4% 
paraformaldehyde and permeabilized in 0.1% Triton-X-100. Staining was done in 3% 
bovine serum albumin (Sigma Chemical Co., St. Louis, MO). 
 
Western immunoblotting  
Cells were harvested after treatment and lysed in buffer containing 5% 1M Tris 
pH 7.0, 2% SDS, and 5% sucrose. Protein concentration was quantified using the Pierce 
BCA Protein Assay according to manufacturer’s instructions. 10-50 μg protein lysate was 
subjected to SDS-PAGE followed by a two hour transfer to PVDF membrane. Blocking 
and antibody incubation were done in 5% milk in PBS containing 0.05% Tween-20. 
Membranes were exposed to X-ray film using the ECL Western Blotting Substrate 
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(Pierce).  Antibodies used in this study included: anti-β-tubulin antibody and anti-γ-
tubulin (Sigma Chemical Co., St. Louis, MO), anti-Pyk2 and anti-FAK (Upstate Cell 
Signaling Solutions, Lake Placid, NY), and GAPDH (Chemicon International, Temecula, 
CA). Densitometry levels for each blot was determined using β-actin as a loading control; 
relative intensity levels for each sample were plotted and normalized to untreated (UT) 
samples. 
 
Cell Growth and Viability Assays to Determine the Combination Index 
In order to determine how treatment with telomerase template antagonists or 
paclitaxel affect cell growth and viability, 5x104 cells were plated in 12-well dishes in 
triplicate and were treated with 1:2 serial dilutions of GRN163L (0.005-1.25 μM) or 
paclitaxel (0.5-12.5 nM) in culture media. Cells were then collected after five days to 
obtain cell number and viability as measured by the Trypan blue exclusion assay.  
Percent inhibition of cell growth compared to untreated cells was determined and plotted.  
In order to determine the effects of combination therapy on breast cancer cells, parallel 
studies were done in which cells were treated with 1:2 serial dilutions of GRN163L or 
mismatch oligonucleotides (0.005-2.5 μM) in combination with paclitaxel (0.5-12.5 
nM), in which the two agents were at a 1:10 ratio of each other (paclitaxel: GRN163L). 
CalcuSyn software (Biosoft, Cambridge, United Kingdom) was used to determine the 
combined effect of multiple drug treatment via the Chou and Talalay method (Chou and 
Talalay 1984). This program analyzes the effect of combining drugs with different 
mechanisms of action in order to determine whether single drug therapy is improved 
upon the addition of a second compound. A combination index (CI) value of <1.0 
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denotes synergistic interaction (more than additive), a CI of 1.0 demonstrates summation 
(additive), and a CI >1.0 indicates antagonistic interaction (less than additive). 
 
Xenograft mice studies 
Athymic nude mice (nu/nu; Harlan Sprague-Dawley, Inc., Indianapolis, IN) were 
maintained in pathogen-free conditions within the Laboratory Animal Resources Center 
at the Indiana University School of Medicine according to an approved protocol by 
institutional Laboratory Animal Resources Center and Institutional Animal Care and Use 
Committee. 1x106 MDA-MB-231 breast cancer cells were injected into the mammary fat 
pads of 6- to 8-weekold mice. Following a recovery period of 2 days, mice began 
receiving treatment of 30 mg/kg GRN163L (n = 30) or a PBS solvent control (n = 30) 
three times weekly intraperitoneally (IP) or 15 mg/kg paclitaxel (n=30) once weekly via 
IP, alone or in combination with 30 mg/kg GRN163L (n=30). Average weight of animals 
and size of tumors were similar among treatment groups. Tumor volume was calculated 
as (length x width2) / 2 (in mm3). Student’s t-test was performed using Microsoft Excel. 
 
Cell invasion assay 
Matrigel invasion assays were performed using the Cell Invasion Assay kit from 
Chemicon International (Temecula, CA) as per manufacturer’s protocol. MDA-MB-231 
cells were treated with 0.156-0.3125 μM GRN163L or mismatch oligonucleotides or 16-
31 nM paclitaxel for five days. In order to determine the effects of combination therapy 
on the invasive potential of MDA-MB-231 breast cancer cells, parallel studies were done 
in which cells were treated with 0.156-0.3125 μM GRN163L or mismatch 
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oligonucleotides in combination with paclitaxel (16-31 nM), in which the two agents 
were at a 1:10 ratio of each other. The invasion assay was performed using 1.5 x 105 cells 
per well without further addition of drug. The bottom chamber of the invasion chambers 
contained media with 10% cosmic calf serum (HyClone, Logan, UT) as a 
chemoattractant. Invasion was measured 24 hours after plating. Stained cells were 
dissolved in 10% acetic acid and the absorbance read at 560 nm. Student’s t-test was 
performed using Microsoft Excel. 
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Chapter Four 
Telomerase Template Antagonists Augment the Effects of Trastuzumab in HER2-
positive Breast Cancer Cells  
This work is reprinted from Breast Cancer Research and Treatment; Erin M. Goldblatt, 
Priscilla A. Erickson, Erin R. Gentry, Sergei M. Gryaznov, and Brittney-Shea Herbert, 
“Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive 
breast cancer cells to trastuzumab,”  DOI: 10.1007/s10549-008-0201-4 (2008) with 
permission from Springer. 
 
 
Abstract 
HER2 amplification is found in 10-20% of breast cancers and is associated with a 
more aggressive disease, greater likelihood of recurrence, and decreased survival 
compared to women with HER2-negative (HER2-) breast cancer. Trastuzumab is a 
monoclonal antibody that inhibits HER2 activity, making this compound an important 
therapeutic option for patients with HER2-positive (HER2+) breast cancer. However, 
resistance to trastuzumab develops rapidly in a large number of breast cancer patients. 
The objective of this study was to determine whether GRN163L, a telomerase template 
antagonist currently in clinical trials for cancer treatment, can augment the effects of 
trastuzumab in breast cancer cells with HER2 amplification. Results demonstrate that 
GRN163L is an effective telomerase inhibitor and shortens telomeres in HER2+ breast 
cancer cells. Additionally, combining GRN163L with trastuzumab synergistically inhibits 
HER2-positive breast cancer cell growth. More importantly, GRN163L restored the 
sensitivity of therapeutically resistant breast cancer cells to trastuzumab. These findings 
implicate that telomerase template antagonists have potential use in the treatment of 
cancers that have developed resistance to traditional cancer therapy. 
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Introduction 
 HER2 (human epidermal growth factor receptor 2) is a member of the 
ErbB/EGFR family of transmembrane receptor tyrosine kinases that plays a role in tumor 
cell growth, invasion, and metastasis (Slamon et al. 2001, Ross et al. 2004, Hudis 2007). 
HER2 amplification is found in approximately 10-20% of breast cancers and is associated 
with a more aggressive disease, greater likelihood of recurrence, poorer prognosis and 
decreased survival compared to women with HER2-negative breast cancer (Ross et al. 
2004, Menendez et al. 2005, Sledge 2004). In addition, HER2 overexpression is 
associated with resistance to chemo- and endocrine therapies (Menendez et al. 2005, 
Burstein 2005, Tan et al. 1997).  
Trastuzumab (Herceptin™) is a monoclonal antibody that binds the extracellular 
portion of HER2 and is thought to induce antibody-dependent cellular cytotoxicity, 
prevent receptor activation and signaling, inhibit angiogenesis, and induce apoptosis 
(Ross et al. 2004, Hudis 2007). Trastuzumab has become an important therapeutic option 
for patients with HER2-positive breast cancer and is widely used for treating advanced 
metastatic disease (Sledge 2004, Ross et al. 2003). Importantly, trastuzumab works well 
in combination with many chemotherapy agents, resulting in better response to treatment, 
increased time to disease progression, and increased survival (Nicolini et al. 2006, 
Pegram et al. 2004, Ross 2003). Trastuzumab administration, however, can be associated 
with adverse side effects including ventricular dysfunction, cardiac failure, infusion 
reactions, and pulmonary events (Sledge 2004, Pegram et al. 2004). In addition, not all 
HER2 overexpressing breast cancer cells respond to trastuzumab treatment as resistance 
develops rapidly in a large number of patients (Menendez et al. 2005, Burstein 2005, Tan 
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et al. 1997, Nahta et al. 2007a, Nahta et al. 2007b). Importantly, the negative side effects 
of trastuzumab can be exacerbated by the effects of chemotherapy drugs or radiation. 
It has been proposed that HER2 amplification is associated with increased 
telomerase (hTERT) expression and telomerase activity in breast cancer tissue samples 
and cell lines (Goueli et al. 2004), although this association remains controversial. 
Telomerase is essential for unlimited cellular proliferation and tumorigenesis and has 
been shown to be increased in almost all human malignancies as compared to benign 
lesions (Shay and Bacchetti 1997, Kim et al. 1994). Telomerase inhibition results in the 
erosion of telomeric DNA, genomic instability, and eventually to apoptosis or senescence 
(Herbert et al. 2005, Gellert et al. 2006, Shay 2003, Hochreiter et al. 2006, Dikmen et al. 
2005). Previous studies from our laboratory have shown that the telomerase template 
antagonist GRN163L, currently in clinical trials, inhibits telomerase activity, shortens 
telomeres, and reduces colony formation ability and replicative capacity of breast cancer 
cells. We also showed that GRN163L reduces tumor growth and metastasis of human 
breast cancer cells in vivo (Hochreiter et al. 2006). Inhibiting telomerase activity may 
affect how breast cancer cells respond to other therapy by reducing the ability for 
continual cellular replication. This suggests that the use of telomerase inhibitors in 
therapy regimens may be clinically applicable in the treatment of breast cancers, 
including the HER2 subset.  
The purpose of this study was to determine whether the telomerase template 
antagonist GRN163L can augment the effects of trastuzumab in breast cancer cells with 
HER2 amplification. The combined effects of HER2 inhibition by trastuzumab and 
telomerase inhibition resulted in synergistic inhibition of breast cancer cell growth. In 
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addition, GRN163L, alone and in combination with trastuzumab, inhibited the growth 
breast cancer cells that had acquired resistance to trastuzumab. These results provide new 
insight into new strategies into the treatment of this particular subset of breast cancers.  
 
Results 
Lipid-conjugated thio-phosphoramidate telomerase template antagonists inhibit 
telomerase activity and shorten telomeres in HER2-amplified breast cancer cells 
HER2 amplification has been linked with an increase in hTERT expression and 
telomerase activity in breast tumor tissue and cell lines (Goueli et al. 2004), which 
indicates that the use of telomerase inhibitors in therapy regimens for HER2 breast 
cancers may be clinically applicable. To test the hypothesis that HER2+ breast cancers 
have elevated telomerase activity levels compared to HER2- breast cancers, the baseline 
telomerase activity was determined in both HER2+ and HER2- breast cancer cell lines 
(Figure 4.1). In addition, the baseline protein levels of HER2 were determined. MDA-
MB-231 breast cancer cells, which do not have HER2 amplification, had one of the 
lowest baseline telomerase activity levels of all cell lines tested, as well as nondetectable 
levels of HER2 expression. Both the MCF7/HER2 cells, which have exogenous HER2 
expression, and trastuzumab-resistant SKBR3-R cells exhibited the highest amount of 
telomerase activity compared to their parental MCF7 (an empty vector infected MCF7 
cells) and SKBR3 cells, respectively.  
To validate lipid-conjugated thio-phosphoramidates as effective telomerase 
inhibitors in breast cancer cell lines with HER2 overexpression, cells were  
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Figure 4.1. Telomerase activity levels and HER2 levels.  Comparison of the baseline 
telomerase activity and HER2 protein levels in HER2+ vs. non-HER2 subtype breast 
cancer cells. Telomerase activity was analyzed using the Telomerase Repeat 
Amplification Assay (TRAP) with MDA-MB-231, SKBR3, BT-474, MCF7 pcDNA, or 
MCF7/HER2- breast cancer cells. Results shown are the telomerase products depicted as 
a ladder. A positive control cell extract (TRAPeze® Telomerase Detection kit) and NP-40 
lysis buffer (LB) were used as a positive and negative control, respectively. HI= heat 
inactivated control samples; IC= internal control. Lower panel depicts HER2 expression 
by western immunoblotting where 15 μg protein was loaded for all cells with HER2 
amplification, and 50μg protein was loaded for the non-HER2 subtypes (231 and MCF-
7pcDNA cells). β-actin served as a loading control.   
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treated with a 1:10 serial dilution series of two telomerase template antagonists, 
GRN163L and 5'oleic163 (0.001-10 μM), for 24 hrs and collected for analysis of 
telomerase activity levels. Previous reports have shown that oleic acid, the main 
monounsaturated fat in olive oil, can regulate HER2 expression and activity (Menendez 
et al. 2005, Menendez et al. 2004, Menendez et al. 2007). This can in turn inhibit cell 
proliferation, induce apoptosis, and alter downstream targets of HER2 signaling in 
HER2+ breast cancer cells. These reports also showed that oleic acid worked 
synergistically with trastuzumab to enhance the effects of either drug alone (Menendez et 
al. 2004, Menendez et al. 2007). To this end, the inhibition of telomerase activity induced 
by 5'oleic163 was compared to the inhibition induced by GRN163L to determine whether 
the type of the lipid group (oleic versus palmitoyl) would make a difference in the level 
of telomerase inhibition in HER2+ breast cancer cells. The EC50 for telomerase inhibition 
was in the low nM range for both compounds, indicating the universal potency of 
lipidated telomerase inhibitors (Herbert et al. 2005; data not shown). Both telomerase 
template antagonists inhibited telomerase activity in a dose-dependent manner regardless 
of HER2 status (Figure 4.2; Hochreiter et al. 2006).  
We and others previously reported that GRN163L progressively shortens 
telomeres in a wide range of breast cancer cell lines (Herbert et al. 2005, Gellert et al. 
2006, Hochreiter et al. 2006, Dikmen et al. 2005, Gomez-Millan et al. 2007). To confirm 
that treatment with telomerase template antagonists also efficiently shortens telomeres in 
HER2+ breast cancer cells, SKBR3 cells were grown for eight weeks in the presence of 
GRN163L, 5'oleic163, or mismatch oligonucleotides. Treatment with GRN163L and 
5'oleic163 resulted in progressive telomere shortening, averaging ~100 bp per  
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Figure 4.2. Effects of lipid-conjugated telomerase template antagonists on 
telomerase activity in HER2+ breast cancer cells. Telomerase template antagonists 
effectively inhibit telomerase activity in breast cancer cells in a dose-dependent fashion 
regardless of HER2 status. Breast cancer cells were treated with a 1:10 serial dilution of 
0.001-10 μM 5'oleic163. Cells were collected after 24-72 hours for telomerase activity 
assays. MDA-MB-231, MCF7 pcDNA, and BT-474 samples demonstrate telomerase 
inhibition after 24 hours. MCF7/HER2 and SKBR3 cells, which have higher baseline 
telomerase activity, also take longer for inhibition (48-72 hours respectively).  Relative 
telomerase activity was determined as in Figure 4.1 and is depicted as arbitrary units 
(AU). Results are representative of multiple, independent experiments.  
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population doubling compared with untreated or mismatch control treated cells 
(Hochreiter et al. 2006; data not shown), confirming that telomerase template antagonists 
are effective at inhibiting telomere maintenance and survival in HER2+ breast cancer 
cells. 
 
GRN163L significantly inhibits cell proliferation  
To determine the effect of treatment with GRN163L on HER2+ breast cancer cell 
growth, SKBR3 and BT474 cells were plated onto tissue culture dishes in triplicate. As 
shown in Figure 4.3a, treatment with GRN163L inhibited SKBR3 breast cancer cell 
growth over time. Treatment with mismatch oligonucleotide had no effect on cell growth, 
indicating that the effect on cell growth is not related to the use of lipidated 
oligonucleotides, but is intrinsic to the telomerase template antagonist. The total 
population doublings per week were calculated to determine the rate of growth inhibition. 
As shown in Figure 4.3b, the average time for one population doubling increased from 
2.4 days in untreated cells, to 4 days in cells treated with GRN163L. As expected, the 
mismatch oligonucleotide again had no effect on population doubling time. Similar 
results were seen with BT74 and MCF7/HER2 cells (data not shown). 
 
Telomerase template antagonists synergistically enhance the effects of trastuzumab on 
inhibiting cell proliferation in HER2+ breast cancer cells 
To determine whether the GRN163L can augment the inhibitory effects of 
trastuzumab on cell growth in HER2+ breast cancer cells, SKBR3 cells were plated  
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Figure 4.3. Effects of GRN163L on HER2+ breast cancer cell growth. (A) 5 x 104 
SKBR3 cells were plated in 6-well plates in triplicate. Cells were treated with 2.5 μM 
GRN163L or mismatch (MM) oligonucleotide, replenishing the drug every third day. 
After 7 days, cells were collected and counted to determine population doublings. Each 
sample was counted in triplicate. Samples were combined before replating to avoid 
selection for resistant cells. (B) Average doubling time (in days) was determined for in 
response to GRN163L or mismatch (MM) oligonucleotides. GRN163L significantly 
increases the average time for the population of SKBR3 cells to double once (in days, p = 
0.0015). Mismatch oligonucleotide has no effect on doubling time (p = 0.095). Student’s 
t-test was performed using Microsoft Excel. 
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with 0.0195-10 µM GRN163L either alone or with 0.005-2.5 µM trastuzumab for five 
days. Cells were collected and counted to determine the effect of individual or 
combination therapy on cell growth and viability. SKBR3 cells demonstrated a dose-
dependent response to growth inhibition by trastuzumab and GRN163L (Figure 4.4). A 
lipidated, mismatch oligonucleotide control did not exhibit significant effects on cell 
growth inhibition. The combination of GRN163L and trastuzumab resulted in a 
significant shift in the growth inhibition curve compared to either agent alone (Figure 4.4, 
upper panel). Low doses of GRN163L were used to rule out any possible toxicity induced 
by the oligonucleotide. The synergistic effect of combination treatment was found even at 
low nM doses of GRN163L, where telomerase is still inhibited. In addition, the mismatch 
control did not alter the growth inhibition effects of trastuzumab. The statistical 
combination index (CI) was determined for the dual therapy to determine whether 
combination therapy was synergistic, additive, or antagonistic. As shown in Figure 4.4 
(lower panel), GRN163L acted synergistically with trastuzumab to inhibit cell growth of 
SKBR3 cells at all combination doses tested. Furthermore, similar observations were 
made for SKBR3 cells which exhibited a large population of short, dysfunctional 
telomeres (Hochreiter et al. 2006) due to extended treatment with the telomerase 
inhibitors (Table 4.1). Similar results were obtained with a 5'oleic163, suggesting that the 
specific lipid group modification did not make a difference in HER2+ breast cancer cells 
(Table 4.2). 
To determine whether the synergism between lipid-conjugated telomerase 
template antagonists and trastuzumab could be observed in other cell lines, BT474 
(HER2+) breast cancer cells were treated as above to determine percent growth  
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Figure 4.4. GRN163L augments the effects of trastuzumab in HER2+ SKBR3 breast 
cancer cells.  SKBR3 cells were plated in 12-well dishes and treated with 1:2 serial 
dilutions of GRN163L or a mismatch oligonucleotide alone (MM), trastuzumab alone, or 
the combination of GRN163L/MM with trastuzumab at a 1:4 ratio (trastuzumab: 
GRN163L/MM).  Cells were collected after five days to determine cell number and 
viability. Percent inhibition was plotted versus concentration for each treatment group 
(top panel). Calcusyn software (Biosoft, Cambridge UK) was used to ascertain the 
combination index (CI) value for each combination ratio (Dose), from highest to lowest 
(bottom to top) to determine whether combination treatments have an additive or 
synergistic effect (lower panel; ±SD). A CI value of CI <1.0 denotes synergistic 
interaction (more than additive), a CI of 1.0 demonstrates summation (additive), and a CI 
>1.0 indicates antagonistic interaction (less than additive).  
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Table 4.1.  Combination treatments with GRN163L and trastuzumab synergistically 
inhibit cell growth of SKBR3 breast cancer cells pre-treated with GRN163L to 
induce telomere shortening. 
 
 
Sample: 
Trastuzumab 
(μM) 
GRN163L 
(μM) Ratio 
% Growth 
Inhibition 
Fold increase  
(vs. 
Trastuzumab) 
CI 
value 
SKBR3+GRN163L 
(10-15 weeks) 2.5 10 1:4 69.5 ± 4.1 1.77 0.111 
 
1.25 5 1:4 50.1 ± 2.5 1.34 0.297 
 
0.625 2.5 1:4 40.8 ± 10.6 1.35 0.323 
 
0.3125 1.25 1:4 33.91 ± 0.8 1.46 0.299 
 
0.156 0.625 1:4 30.33 ± 1.0 2.16 0.212 
 
 
 
 
Cells were treated with a 1:4 combination (Ratio) of trastuzumab: GRN163L at the 
indicated concentrations. Percent growth inhibition of the combination treatments was 
calculated compared to untreated (media only) cells. The fold increase in percent growth 
inhibition of the combination treatment compared to trastuzumab alone was calculated 
(Fold increase). Calcusyn software (Biosoft, Cambridge UK) was used to ascertain the 
combination index to determine whether combination treatments have an additive or 
synergistic effect. A combination index (CI) value of CI <1.0 denotes synergistic 
interaction (more than additive), a CI of 1.0 demonstrates summation (additive), and a CI 
>1.0 indicates antagonistic interaction (less than additive).  
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Table 4.2.  Combination treatments with 5'oleic163 and trastuzumab synergistically 
inhibit breast cancer cell growth. 
 
Cell line: 
Trastuzumab 
(μM) 
5'oleic163 
(μM) Ratio 
% Growth 
Inhibition 
Fold increase  
(vs. Trastuzumab) 
CI 
value 
SKBR3 2.5 10 1:4 58.4 ± 1.2 1.25 0.527 
 1.25 5 1:4 56.31 ± 0.03 1.35 0.307 
 0.625 2.5 1:4 52.6 ± 1.0 1.36 0.209 
 0.3125 1.25 1:4 48.3 ± 1.2 1.35 0.161 
 0.156 0.625 1:4 45.2 ± 3.9 1.5 0.116 
SKBR3-R  2.5 10 1:4  80.4 ± 3.5 11.14 0.162 
 
1.25 5 1:4 76.6 ± 3.1 12.38 0.132 
 
0.625 2.5 1:4 72.7 ± 4.2 20.21 0.103 
 
0.3125 1.25 1:4 68.3 ± 6.0 26.59 0.082 
 
0.156 0.625 1:4 65.5 ± 6.3 63.85 0.054 
 
 
 
Cells were treated with a 1:4 combination (Ratio) of trastuzumab: 5’oleic163 at the 
indicated concentrations.   Percent growth inhibition of the combination treatments was 
calculated compared to untreated (media only) cells. The fold increase in percent growth 
inhibition of the combination treatment compared to trastuzumab alone was calculated 
(Fold increase). Calcusyn software (Biosoft, Cambridge UK) was used to ascertain the 
combination index to determine whether combination treatments have an additive or 
synergistic effect. A combination index (CI) value of CI <1.0 denotes synergistic 
interaction (more than additive), a CI of 1.0 demonstrates summation (additive), and a CI 
>1.0 indicates antagonistic interaction (less than additive). 
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inhibition compared to untreated cells as well as the combination index. BT474 cells also 
showed a similar response to growth inhibition by trastuzumab and GRN163L as with the 
SKBR3 cells (Figure 4.5, upper panel). As with the SKBR3 cells, dual therapy of 
GRN163L and trastuzumab had synergistic effects on inhibiting cell growth of BT474 
cells at all combination doses tested (Figure 4.5, lower panel). In addition, MCF7 cells 
overexpressing HER2 (MCF7/HER2) treated with GRN163L and trastuzumab also 
showed synergistic effects on cell proliferation. The combination of GRN163L and 
trastuzumab was synergistic (CI <1.0) for cell growth inhibition at all dose combinations 
tested for MCF7/HER2 cells. MCF7 control cells (MCF7pcDNA) did not respond to 
trastuzumab, no additional growth inhibitory effect was seen when combined with 
GRN163L or 5'oleic163 in these cells, and the combination index was greater than 1.0 
(Table 4.3; data not shown).   
 
Telomerase template antagonists in combination with trastuzumab inhibit the growth of 
trastuzumab-resistant HER2+ breast cancer cells. 
To determine the effects of combination treatment on HER2+ breast cancer cells, 
the sensitivity to trastuzumab was first tested in both parental and trastuzumab-resistant  
SKBR3 cells. Parental SKBR3 cells had an 83% reduction in growth in response to 10 
μg/ml trastuzumab (p < 0.001), whereas trastuzumab-resistant SKBR3-R cells had <10% 
reduction in growth in response to 10-20 μg/ml of trastuzumab (data not shown), which 
corroborated previously published reports (Nahta et al. 2004). Interestingly, the 
trastuzumab-resistant SKBR3-R cells were more sensitive to both telomerase inhibitors 
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Figure 4.5. GRN163L augments the effects of trastuzumab in HER2+ BT474 breast 
cancer cells.  BT474 cells were plated as in Figure 4.4. Cells were collected after five 
days to determine cell number (and viability). Percent growth inhibition was plotted 
versus concentration for each treatment group (top panel). Calcusyn software (Biosoft, 
Cambridge UK) was used to ascertain the combination index (CI) value for each 
combination ratio (Dose), from highest to lowest (bottom to top) to determine whether 
combination treatments have an additive or synergistic effect (lower panel; ±SD).  
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Table 4.3.  Combination treatments with GRN163L and trastuzumab synergistically 
inhibit cell growth of MCF7 breast cancer cells overexpressing HER2, but not 
MCF7pcDNA cells. 
 
 
Cell line: Trastuzumab (μM) 
GRN163L 
(μM) Ratio CI value 
Fold increase in growth 
inhibition 
vs. trastuzumab alone  
(MCF7/HER2 cells only) 
MCF7pcDNA 2.5 10 1:4 1.522  
 
1.25 5 1:4 1.099  
 
0.625 2.5 1:4 1.050  
 
0.3125 1.25 1:4 1.026  
 
0.156 0.625 1:4 1.133  
MCF7/HER2 2.5 10 1:4 0.100 2.68 
 1.25 5 1:4 0.137 2.93 
 0.625 2.5 1:4 0.135 3.05 
 0.3125 1.25 1:4 0.154 4.21 
 0.156 0.625 1:4 0.146 4.71 
 
 
 
Cells were treated with a 1:4 combination (Ratio) of trastuzumab: GRN163L at the 
indicated concentrations. Percent growth inhibition of the combination treatments was 
calculated compared to untreated (media only) cells. Calcusyn software (Biosoft, 
Cambridge UK) was used to ascertain the combination index to determine whether 
combination treatments have an additive or synergistic effect. A combination index (CI) 
value of CI <1.0 denotes synergistic interaction (more than additive), a CI of 1.0 
demonstrates summation (additive), and a CI >1.0 indicates antagonistic interaction (less 
than additive). The fold increase in percent growth inhibition of the combination 
treatment compared to trastuzumab alone was calculated for MCF7/HER2 cells only 
which had a CI index of < 1.0. 
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compared to the parental SKBR3 cells. More importantly, telomerase inhibitors in 
combination with trastuzumab resulted in synergistic effects (CI < 1.0) on cell growth 
inhibition compared to either agent alone (Figure 4.6, bottom panel) at all combination 
doses tested. BT474 cells that had acquired resistance to trastuzumab (BT474-R), as 
previously described (Ritter et al. 2007), also showed enhanced sensitivity to the 
combination of GRN163L and trastuzumab compared to either agent alone (Figure 4.7).  
The combination index for BT474-R cells at all doses was also <1.0 (Figure 4.7, bottom 
panel). 
 
GRN163L and trastuzumab, alone or in combination, have no significant effect on cell 
growth of non-tumorigenic human mammary epithelial cells (HMECs) and MCF10A 
cells.   
To determine whether the effects of lipid-conjugated telomerase template 
antagonists and trastuzumab on cancer cell growth could also be seen in non-tumorigenic 
breast epithelial cells, HMECs from a patient with no history of breast cancer as well as 
the non-tumorigenic MCF10A cells were treated in the same manner as in the 
experiments with the SKBR3 and BT474 cells. These cells do not contain amplified 
levels of HER2 and are not expected to be sensitive to trastuzumab. As shown in Figure 
4.8, GRN163L, a mismatch oligonucleotide control, and trastuzumab had no significant 
effect on the proliferation of HMECs and MCF10A cells, either alone or in combination. 
These results further support the suggestion of specificity of telomerase template 
antagonists towards cancer cells without limiting the proliferation and viability of normal 
cells.  
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Figure 4.6. GRN163L in combination with trastuzumab inhibits cell proliferation in 
trastuzumab-resistant SKBR3 breast cancer cells. Trastuzumab-resistant SKBR3-R 
breast cancer cells were plated and treated as in Figure 4.4. Percent growth inhibition 
compared to untreated (media only) cells was plotted versus each versus concentration 
for each treatment group (top panel). Combination index value for each dose combination 
is shown on the bottom panel.  Results are representative of multiple, independent 
experiments (± SD). 
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Figure 4.7. GRN163L in combination with trastuzumab inhibits cell proliferation in 
trastuzumab-resistant BT474 breast cancer cells. Trastuzumab-resistant BT474-R 
breast cancer cells were plated and treated as in Figure 4.4. Percent growth inhibition 
compared to untreated (media only) cells was plotted versus each versus concentration 
for each treatment group (top panel). Combination index value for each dose combination 
is shown on the bottom panel.  Results are representative of multiple, independent 
experiments (± SD). 
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Figure 4.8. GRN163L and trastuzumab have no affect on cell growth of 
nontumorigenic human mammary epithelial cells (HMECs) and MCF10A cells.  
HMECs and MCF10A cells were plated, treated with GRN163L, it mismatch control, and 
trastuzumab, and analyzed for their effects on cell growth inhibition as described for 
Figure 4.4.  GRN163L and trastuzumab treatment showed no significant effect on HMEC 
or MCF10A cell growth. Results are representative of multiple, independent experiments 
(± SD). 
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Effect of telomerase inhibitors on HER2 expression and activity 
In an effort to understand the mechanism underlying the response to combination 
treatment with of GRN163L and trastuzumab, the level of HER2 and phosphorylated 
HER2 levels in SKBR3 and SKBR3-R cells was determined by Western blotting. 
5'oleic163, GRN163 (non-lipidated), GRN163L (palmitoyl acid group), oleic acid, and 
mismatch oligonucleotide treated samples were used to determine whether the presence 
or type of lipid group was vital for the effect on HER2 expression. In addition, 
 SKBR3 cells were treated with the EC50 (for phosphorylated HER2 levels) concentration 
of trastuzumab (10 µg/ml) as a positive control. As expected, SKBR3-R cells did not 
exhibit a significant decrease in phosphorylated HER2 levels after treatment with HER2 
inhibitors as expected. As an additional test for HER2 inhibition in resistant SKBR3 
cells, the selective HER2 tyrosine kinase inhibitor AG825 was used.  In our hands, 
AG825 did not decrease phosphorylated HER2 levels in the SKBR3-R cells which may 
reflect lost sensitivity to this kinase inhibitor in these cells. These results demonstrate that 
none of the compounds tested had a significant effect on the level of basal HER2 
expression (Figure 4.9). Interestingly, GRN163L decreased the expression of 
phosphorylated HER2 by ~90% in both parental and trastuzumab-resistant SKBR3 cells 
(Figure 4.9). This decrease in HER2 phosphorylation may underlie the synergistic effect 
of combination therapy with GRN163L and trastuzumab on HER2+ breast cancer cell 
growth. The combination of GRN163L and trastuzumab (at the doses used in Figures 4.4-
4.8) also displayed reduced levels of phosphorylated HER2 (data not shown). Similarly, 
the level of phosphorylated HER2 in the MCF7/HER2 cells was decreased by 50-70% 
upon treatment with GRN163L or GRN163, indicating that the lipid group was not a key 
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factor (Figure 4.10). Additionally, MCF7/HER2 cells were treated with 20 μg/ml 
trastuzumab as a postitive control. Treatment with trastuzumab resulted in approximately 
90% inhibition of phosphorylated HER2. In all cell lines tested, a mismatch control 
oligonucleotide did not significantly alter HER2 levels. However, phosphorylated HER2 
levels were altered upon oligonucleotide treatment after 48 hours in the SKBR3 and 
SKBR3-R cells (Figure 4.9) inhibition with trastuzumab after 5 days (Figures 4.4 and 
4.5). This may reflect a temporal change in phosphorylated HER2 levels as mismatch 
oligonucleotide treatment of the MCF7/HER2 cells did not result in changes in 
phosphorylated HER2 levels (Figure 4.10). It has been reported that in trastuzumab-
resistant BT474 cells, the level of EGFR and phosphorylated EGFR was significantly 
increased, and that inhibition of that phosphorylation via lapatinib (a dual tyrosine kinase 
inhibitor for EGFR and HER2) could inhibit cell growth (Ritter et al. 2007).To determine 
whether the combination of GRN163L and trastuzumab was acting in a similar fashion, 
the level of phosphorylated EGFR was measured via ELISA in the BT474 parental and 
resistant cells at the same time point as performed for Figures 4.4-4.8 (5 days). Treatment 
with GRN163L did not, however, result in a significant decrease in the level of EGFR 
phosphorylation in response to GRN163L (data not shown). These results indicate that 
the growth inhibition induced by GRN163L in combination with trastuzumab may be 
complex and require further investigation. 
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Figure 4.9. Effects of telomerase template antagonists on HER2 expression and 
signaling in SKBR3 cells. Western immunoblotting was performed to examine HER2 
and phosphorylated HER2 (P-HER2) protein expression in treated cells. Both 
trastuzumab sensitive (SKBR3) or trastuzumab-resistant (SKBR3-R) breast cancer cells 
were treated with 10 μM oleic acid,  5-10 μM 5'oleic163, GRN163L, GRN163, or 
mismatch (MM) oligonucleotides for 48 hours following a 24 hour serum starvation. The 
selective HER2 tyrosine kinase inhibitor AG825 (5 μM) and/or trastuzumab (10 μg/mL; 
EC50) were used as positive controls for HER2 inhibition. Untreated (media only) MCF7 
cells were used as a negative control, as this cell line does not have HER2 amplification. 
Densitometry levels for each blot was determined using β-actin as a loading control; 
relative intensity levels for each sample were plotted and normalized to untreated (UT) 
samples. Results are representative of at least two experiments.  
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Figure 4.10. Effects of telomerase template antagonists on HER2 expression and 
signaling in MCF7/HER2 cells. MCF7 cells overexpressing HER2 (MCF7/HER2) were 
treated under estrogen-free conditions with 10 μM oleic acid, 5'oleic163, GRN163L, 
GRN163, or mismatch (MM) oligonucleotides for 48 hours following a 24 hour serum 
starvation. Western immunoblotting for HER2 and phosphorylated HER2 (P-HER2) was 
performed. AG825 (5 μM) and trastuzumab (20 μg/mL) were used as positive controls 
for P-HER2 inhibition. Untreated (media only) MCF7pcDNA (empty vector control) 
cells were used as a negative control, as this cell line does not have HER2 amplification. 
Densitometry levels were determined by comparing intensity of P-HER2 and HER2 to β-
actin levels and relative intensity levels for each sample were plotted and normalized to 
untreated (UT) samples.  
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Discussion 
Trastuzumab administration in breast cancer therapeutic regimens has had a major 
impact on the treatment of HER2+ metastatic breast cancer. Adding trastuzumab to 
therapy regimens has been associated with a longer time to disease progression, higher  
rate of treatment response, longer survival time, and lower death rates (Ross et al. 2003). 
However, trastuzumab can also fail to prevent breast cancer relapse due to acquired 
resistance (Nicolini et al. 2006, Sledge 2004). Therefore, experimental therapeutic 
studies, such as those presented herein, allow for the continued development of improved 
combination therapy for breast cancer using multiple molecular targets. Combining 
chemotherapy drugs or irradiation (IR) with trastuzumab enhances the effects of these 
anti-cancer therapies (Pegram et al. 2004, Liang et al. 2003). However, the negative side 
effects of trastuzumab can be exacerbated by the effects of chemotherapy drugs or IR. 
The effect of telomerase inhibition in sensitizing cancer cells to chemotherapy drugs and 
IR is well documented, but has been shown to require telomere shortening prior to 
detecting sensitization, indicating a long lag time (Cerone et al. 2006a, Djojosubroto et al. 
2005, Gomez-Millan et al. 2007, Ward and Autexier 2005). The data presented here 
shows that telomerase template antagonists can significantly increase the sensitivity of 
HER2-positive breast cancers to trastuzumab within five days, including cells which have 
developed resistance to HER2 inhibition. These results have significant implications for 
the treatment of breast cancers that have acquired resistance to anti-HER2 therapies.  As 
shown by the efficient uptake and inhibition of telomerase activity (Figure 4.1, page 94), 
the oligonucleotide telomerase inhibitors used in this study may therefore be effective in 
limiting relapse and delaying recurrence in HER2 breast cancer cells. This may be a 
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novel use for a telomerase template antagonist that does not depend on telomeres 
becoming critically short prior to inducing growth arrest or cell death. However, we 
cannot rule out a bystander effect of a few dysfunctional telomeres within a few 
population doublings that may play a role in the synergistic effect of telomerase 
inhibitors and targeted therapy. Therefore, treatment with telomerase template 
antagonists in therapeutic regimens could have beneficial outcome not only on primary 
tumor growth due to the effects of telomere shortening, but also in therapeutic regimens 
for sensitization to therapy and prevention of recurrence.  
Dietary fatty acids have been shown to regulate signal-transduction pathways and 
may be associated with the risk of developing many diseases including cancer. This 
relationship between fatty acids and regulation of cell signaling in cancer remains unclear 
(Ip 1997, Hardman 2004, Hwang and Rhee 1999). Previous reports have shown that oleic 
acid, the main monounsaturated fat in olive oil, can regulate HER2 expression and 
activity (Menendez et al. 2004, Menendez et al. 2005, Menendez et al. 2007). This 
regulation can in turn inhibit cell proliferation, induce apoptosis, and alter downstream 
targets of HER2 signaling in breast cancer cells that have HER2 overexpression. The 
reports also showed that oleic acid worked synergistically with trastuzumab to enhance 
the effects of either drug alone (Menendez et al. 2004, Menendez et al. 2007). We 
therefore included within this study an oleic-conjugated telomerase template thio-
phosphoramidate antagonist to test whether the oleic group is important for combination 
effects with trastuzumab on HER2 signaling. The 5'oleic163 thio-phosphoramidate is an 
effective telomerase inhibitor, reducing telomerase activity in a variety of cancer cell 
lines at low nM concentrations without exerting immediate cytotoxicity. However, the 
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oleic-conjugated thio-phosphoramidate displayed similar results as GRN163L in 
combination with trastuzumab, suggesting the type of lipid group was not a key factor in 
the synergism.  
HER2 amplification is also associated with increased hTERT expression and 
telomerase activity (Goueli et al. 2004). How telomerase is regulated within a cell is still 
not completely understood, although numerous reports have shown that telomerase can 
be upregulated through the MAPK pathway (Goueli et al. 2004, Maida et al. 2002, Ge et 
al. 2006). The activation of hTERT can be inhibited by MAPK pathway inhibitors, which 
further supports the role of HER2 signaling in the induction of telomerase activity. In this 
study, however, there was no change in the basal level of HER2 expression after 
treatment with GRN163L, but instead resulted in lower levels of phosphorylated HER2 in 
the breast cancer cell lines tested in this study. Ritter et al. showed that breast cancer cells 
selected for resistance to trastuzumab in vivo overexpressed epidermal growth factor 
receptor (EGFR) and phosphorylated EGFR. Furthermore, this group showed that these 
cells, which contained ErbB ligands, remained dependent on ErbB receptor signaling and 
were sensitive to EGFR tyrosine kinase inhibitors, including the dual EGFR/HER2 
inhibitor lapatinib (Ritter et al. 2007, Nahta et al. 2007b). Ectopic expression of hTERT 
in human mammary epithelial cells is associated with upregulation of EGFR compared to 
untransduced human mammary epithelial cells (Smith et al. 2003). Targeting telomerase 
via siRNA and antisense oligonucleotides (AS-ODNs) in bladder cancer cells resulted in 
the down-regulation of EGFR (Kraemer et al. 2006). We did not, however, observe a 
significant decrease in EGFR or phosphorylated EGFR associated with telomerase 
inhibitor treatment. However, it is likely that the combination of GRN163L and lapatinib 
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would be effective in inhibiting breast cancer cell growth, as trastuzumab-resistant cells 
remain sensitive to both compounds (Ritter et al. 2007, Nahta et al. 2007b). This appears 
to be regulated through insulin-like growth factor I (IGF-I). The involvement of another 
major signaling pathway in trastuzumab-resistant cells indicates that the exact 
mechanisms of GRN163L effects on cell growth inhibition via the HER2/EGFR or IGF-I 
pathway may be complex and warrant further attention. 
In summary, a lipid-conjugated thio-phosphoramidate targeting the RNA template 
region of telomerase (GRN163L) is an effective telomerase inhibitor for HER2+ breast 
cancer cells, as shown by the dose-dependent decrease in telomerase activity and 
progressive telomere shortening with each population doubling. GRN163L, a telomerase 
inhibitor that is currently in clinical trials for cancer therapy, was synergistic with 
trastuzumab to inhibit breast cancer cell growth.  More importantly, telomerase template 
antagonists restored sensitivity to trastuzumab in cells that had acquired resistance.  
These results further support the use of telomerase inhibitors in combination with other 
molecular targeted therapies for the treatment of breast cancer, metastasis, and 
recurrence. Published reports demonstrated synergy between HER2 inhibition via 
trastuzumab and a variety of cytotoxic chemotherapeutic drugs (Pegram et al. 1997, 
Pegram et al. 1999, Liang et al. 2003, Pegram et al. 2004). Despite the benefits of 
combination therapy, many patients have still developed resistance and progressed 
despite therapy, demonstrating the need for research into the mechanisms underlying 
resistance to trastuzumab and how resistance can be reversed. The research presented 
here supports published reports that trastuzumab sensitivity can be restored through 
combination therapy with trastuzumab. This restoration of sensitivity has been studied 
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using IGF-1 receptor signaling inhibitors, and AKT/ PI3K pathway inhibitors. 
Additionally, sensitivity to trastuzumab has been shown to be restored through dual 
therapy with lapatinib and pertuzumab, which inhibits HER2 from binding to EGFR or 
HER3 and initiating downstream signaling pathways (Nahta and Esteva 2006, Nahta and 
Esteva 2007, Suzuki and Toi 2007, Park and Davidson 2007, Berns et al. 2007).  
 
 
Materials and Methods 
Cell culture 
Trastuzumab-resistant and parental SKBR3 cells, a generous gift from Dr. 
Francisco Esteva (UT MD Anderson Cancer Center), were cultured in DMEM/F12 media 
containing 10% fetal bovine serum; resistant cells were cultured with the addition of 4 
μg/ml trastuzumab (Nahta et al. 2004). Trastuzumab-resistant and parental BT-474 cells, 
a generous gift from Dr. Carlos Arteaga (Vanderbilt University School of Medicine), 
were cultured in IMEM (Invitrogen) containing 10% fetal bovine serum; resistant cells 
were cultured with the addition of 10 μg/ml trastuzumab (Ritter et al. 2007). 
MCF7pcDNA and MCF7/HER2 breast cancer cells were kindly provided by Dr. George 
Sledge of the IU Simon Cancer Center (and originally from Dr. Dennis Slamon of 
UCLA). MCF7pcDNA and MCF7/HER2 cells were grown in 1X MEM media containing 
10% fetal bovine serum, 1X non-essential amino acids, and 0.6 mg/ml G418 to maintain 
selection.  Experiments with MCF7 cell lines were performed in phenol red-free media 
containing 2% charcoal stripped fetal bovine serum. All cells were cultured at 37°C and 
5% CO2 and routinely checked for mycoplasma contamination. 
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Reagents 
The telomerase template antagonists used in this study are complementary to the 
telomerase RNA component (hTR) template region for telomerase (5'-
CUAACCCUAAC-3'). The lipid-modified N3'→P5' thio-phosphoramidate 
oligonucleotide (GRN163L, 5'-Palm-TAGGGTTAGACAA-NH2-3') , the non-lipidated 
parental compound (GRN163), the 5'-palmitoyl mismatch control oligonucleotide (5'-
Palm-TAGGTGTAAGCAA-NH2-3'), and the oleic acid conjugated oligonucleotide 
(5'oleic163; 5'-Oleic-TAGGGTTAGACAA-3') were prepared as previously described 
(Herbert et al. 2005). 5'oleic163 was prepared with the substitution of an oleic acid for 
the palmitoyl modification of the GRN163L oligonucleotide. Trastuzumab was kindly 
provided by the Indiana University Cancer Center Pharmacy. The selective HER2 
inhibitor AG825 was purchased from AG Scientific (San Diego, CA) and was dissolved 
as a 10 mM stock in DMSO. Oleic acid (18:1n-9) was purchased from Sigma Chemical 
Co. (St. Louis, MO) and dissolved as a 100 mM stock in ethanol.  
 
Cell Growth and Viability Assays 
In order to determine how treatment with telomerase template antagonists or 
trastuzumab affect cell growth and viability, 5x104 cells were plated with 2.5 μM 
GRN163L or mismatch oligonucleotides in 12-well dishes. Cells were collected weekly 
and counted via Beckman Coulter Counter to determine cell growth. Triplicate samples 
were combined prior to replating to avoid selection of resistant cells. Student’s t-test was 
performed using Microsoft Excel. 
 
120 
Telomere Repeat Amplification Protocol (TRAP) and Telomere Restriction Fragment 
Assay (TRF) 
The TRAP assay was performed using a Cy5 fluorescently labeled TS primer and 
established protocols (Chapter Two; Hochreiter et al. 2006, Herbert et al. 2006). Relative 
telomerase activity (RTA) was calculated as the ratio of the 6-bp telomerase-specific 
ladder to the 36-bp internal standard. The EC50 for telomerase inhibition by the 
telomerase template antagonists was determined using GraphPad Prism (GraphPad 
Software, Inc, San Diego, CA). Measurements of telomere lengths were done as 
described previously (Hochreiter et al. 2006). Average telomere lengths in kb were 
calculated using TELORUN© as previously described (Chapter Two; Herbert et al. 
2003) and plotted versus population doubling (PD) level. 
 
Cell Growth and Viability Assays to Determine the Combination Index 
In order to determine how treatment with telomerase template antagonists or 
trastuzumab affect cell growth and viability, 5x104 cells were plated in 12-well dishes in 
triplicate and were treated with 1:2 serial dilutions of GRN163L (0.0195-10 μM) or 
trastuzumab (0.005-2.5 μM) in culture media. Cells were then collected after five days to 
obtain cell number and viability as measured by the Trypan blue exclusion assay.  
Percent inhibition of cell growth compared to untreated cells was determined and plotted.  
In order to determine the effects of combination therapy on breast cancer cells, parallel 
studies were done in which cells were treated with 1:2 serial dilutions of GRN163L 
(0.0195-10 μM) in combination with trastuzumab (0.005-2.5 μM), in which the two 
agents were at a 1:4 ratio of each other (trastuzumab: GRN163L). A mismatch palmitoyl 
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thio-phosphoramidate oligonucleotide (MM) was used as an oligonucleotide control.  
CalcuSyn software (Biosoft, Cambridge, United Kingdom) was used to determine the 
combined effect of multiple drug treatment via the Chou and Talalay method (Chou and 
Talalay 1984). This program analyzes the effect of combining drugs with different 
mechanisms of action in order to determine whether single drug therapy is improved 
upon the addition of a second compound. A combination index (CI) value of <1.0 
denotes synergistic interaction (more than additive), a CI of 1.0 demonstrates summation 
(additive), and a CI >1.0 indicates antagonistic interaction (less than additive). 
 
Western immunoblotting  
Cells were harvested after treatment and lysed in buffer containing 5% 1M Tris 
pH 7.0, 2% SDS, and 5% sucrose. Protein concentration was quantified using the Pierce 
BCA Protein Assay according to manufacturer’s instructions. 10-50 μg protein lysate was 
subjected to SDS-PAGE followed by a two hour transfer to PVDF membrane. Blocking 
and antibody incubation were done in 5% milk in PBS containing 0.05% Tween-20. 
Membranes were exposed to X-ray film using the ECL Western Blotting Substrate 
(Pierce).  Antibodies used in this study included: anti-c-ErbB2 antibody (Ab-3; Oncogene 
Research Products, San Diego, CA), anti-phospho-HER2 (Cell Signaling Technology; 
Beverly, MD). Densitometry levels for each blot was determined using β-actin as a 
loading control; relative intensity levels for each sample were plotted and normalized to 
untreated (UT) samples. Results are representative of at least two experiments. 
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Chapter Five 
Conclusions and Future Directions 
 
The overall goal of this research project was to gain insight into the role of 
telomerase in breast cancer cell survival and the mechanisms of how the telomerase 
template antagonist GRN163L effectively inhibits the growth of breast cancer cells. In 
vivo studies from our laboratory have shown that telomerase inhibition not only inhibits 
the growth of human breast cancer cells in the mammary fat pad of mice, but also inhibits 
breast cancer metastases to the lung (Hochreiter et al. 2006). Despite individual efficacy, 
telomerase inhibitors have been proposed for use in combination with current therapeutic 
regimens (Shay and Wright 2002). Using combination therapies is likely to improve 
treatment regimens, as targeting multiple pathways involved in cancer progression can 
increase patient survival over single drug therapy. The research presented herein 
demonstrates that in addition to the known telomere dysfunction effects from continuous 
telomerase inhibition, GRN163L induces a rapid inhibitory effect on cell growth and 
invasion. This rapid response synergistically inhibits the growth of breast cancer cells in 
vitro and in vivo with paclitaxel and trastuzumab, supporting the use of this compound in 
the clinical setting. The combination treatments proposed in this study could therefore 
effectively shorten treatment time, thus reducing the negative side effects of 
chemotherapeutic drugs and mortality due to metastatic disease. 
 GRN163L has been shown to be effective in a wide variety of cancer cell lines 
Djojosubroto et al. 2004, Dikmen et al. 2005, Hochreiter et al. 2006, Gellert et al. 2006, 
Gomez-Millan et al. 2007). The combination of telomerase inhibition via GRN163L and 
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irradiation (IR) was shown to significantly enhance the effects of radiation on breast 
cancer cell growth in vitro and primary tumor growth in vivo (Chapter Two; Gomez-
Millan et al. 2007). This effect was shown to be due to the induction of telomere 
dysfunction, suggesting a relationship between extended telomerase inhibition, telomere 
length, and impairment of DNA damage-induced repair. The combination of telomerase 
inhibitors and IR may allow for the use of lower doses of IR, a reduction in the overall 
time of treatment, and a decrease in secondary effects on normal cells. Although 
treatment with GRN163L for 9-20 days did not show any synergism with IR, the 
decrease in proliferation observed during this time period could have a potential clinical 
effect when combined with IR (Gomez-Millan et al. 2007). The in vivo results with 
MDA-MB-231 xenografts support GRN163L as a promising adjuvant cancer treatment in 
combination with radiation therapy (Chapter Two; Gomez-Millan et al. 2007). With 
GRN163L currently in clinical trials, it will be of interest to further study whether other 
tumor models respond to GRN163L in combination with radiation therapy. 
Published reports have demonstrated that inhibiting telomerase activity alone or in 
combination with current therapeutic techniques can inhibit tumor cell growth in vitro 
through telomere dysfunction following protracted telomerase inhibitor treatment (Ward 
and Autexier 2005, Cerone et al. 2006a, Gomez-Millan et al. 2007). The data presented in 
Chapter Three shows that telomerase template antagonists can significantly increase the 
sensitivity of breast cancer cells to paclitaxel at five days, without a significant effect on 
non-tumorigenic cells. This rapid response may be a novel use for a telomerase template 
antagonist that does not depend on the average bulk of telomeres to be shortened prior to 
inducing growth arrest or cell death.  These results indicate that the reduction in 
124 
metastasis observed previously in response to GRN163L (Hochreiter et al. 2006, Jackson 
et al. 2007) could be due to a loss of proliferative potential in breast cancer cells, as 
demonstrated by a reduction in growth rates and DNA synthesis (Chapter Three; 
Hochreiter et al. 2006, Gomez-Millan et al. 2007). Additionally, GRN163L treatment in 
combination with the mitotic inhibitor paclitaxel resulted in reduced or delayed MDA-
MB-231 tumor growth in vivo and invasive potential in vitro. The combination of 
GRN163L and paclitaxel may, therefore, be effective in the treatment of both primary 
and metastatic breast cancer. Furthermore, the data presented in Chapter Four shows that 
telomerase template antagonists can significantly increase the sensitivity of HER2-
positive breast cancers to trastuzumab at five days, including cells which have developed 
resistance to HER2 inhibition.  
Telomerase inhibition results in the lack of maintenance of telomeric DNA and 
eventually leads to apoptosis or senescence (Herbert et al. 2005, Gellert et al. 2006 for 
review, Shay 2003 for review). As discussed previously, the effects of telomerase 
inhibition are predicted to follow a lag phase in which telomeres have reached a critically 
short length due to the end replication problem (i.e., telomeres progressively shorten with 
each cell division). The studies presented in Chapters Two and Three, however, 
demonstrate that there is a rapid response to the second generation, potent telomerase 
template antagonist, GRN163L, which does not rely on the bulk of telomeres to reach a 
critically short state. Published reports have demonstrated that a small number of short 
telomeres are responsible for cell viability rather than the average telomere length of the 
all the chromosomal ends (Zou et al. 2004, Ouellette et al. 2000, Hermann et al. 2001). 
These critically short telomeres may not be accurately measured if present in small 
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numbers, and may trigger growth arrest or cell death without affecting average telomere 
size. The effects of GRN163L on breast cancer cell growth within five days could be due 
to the loss of a sentinel, critically short telomere(s). It would therefore be valuable to 
measure telomere lengths at earlier time points, using sensitive techniques such as 
fluorescence in situ hybridization (FISH) or single telomere length analysis protocol 
(STELA), to determine whether there is a rapid reduction in the size of a small number of 
telomeres, resulting in the shorter response time shown in these studies.  
The balance between cell growth and death is tightly regulated. Resistance to cell 
death, particularly apoptosis, is an important aspect of cancer development and can result 
in resistance to therapy. There are several forms of cell death; apoptosis, autophagy, 
senescence, and mitotic catastrophe (Okada and Mak 2004). Apoptosis is a form of 
programmed cell death, or cellular suicide, which is essential during development and 
tissue homeostasis (Bröker et al. 2005, Okada and Mak 2004). Genomic instability or 
metabolic abnormalities can also trigger apoptosis. This form of cell death is associated 
with chromatin condensation and cellular disintegration, resulting in the elimination of a 
cell that has the potential to become tumorigenic. Senescence is a permanent cell-cycle 
arrest, or terminal growth arrest, after which cells can no longer replicate. This form of 
cell death can be induced by telomere shortening, or through DNA damage. While 
senescent cells remain quiescent, they maintain their viability and metabolic functions. 
Senescent cells are capable of secreting factors that affect the growth of surrounding 
cells, and can have a significant effect on the growth and survival of tumor cells 
(Roninson 2003).  
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Autophagy is a form of cell death seen in the absence of apoptosis. Autophagy is 
associated with the destruction of unwanted or unnecessary proteins and is often activated 
during nutrient starvation or cellular damage. The exact function of autophagy in humans 
is not yet understood, although it is thought to be required for cellular remodeling during 
differentiation, stress, or exposure to cytotoxins (Hait et al. 2006, Okada and Mak 2004). 
Dysregulation of autophagy may result in diseases such as cancer, as some oncogenes 
and tumor suppressor genes play a role in the autophagic process. Additionally, at least 
one of the major proteins involved in autophagy has been found to be located to a human 
tumor-susceptibility locus and is deleted in a high percentage of human epithelial 
cancers, including breast cancer (Okada and Mak 2004, Hait et al. 2006). Furthermore, 
tumor cells that have been treated with anticancer drugs (chemotherapy and molecular 
targeted therapy) can activate the autophagy pathway, although whether this is a 
protective response or a death promoting activity is still unclear (Okada and Mak 2004, 
Hait et al. 2006). Autophagy can be measured by the appearance of cytoplasmic vesicles 
(autophagosomes) that engulf non-essential cellular components such as mitochondria 
and endoplasmic reticulum (Kroemer and Jäättelä 2005, Gozuacik and Kimchi 2004). 
The formation of autophagosomes is visible using electron microscopy. The microtubule-
associated protein-1 light chain-3 (LC3) can be physically associated with forming 
autophagic vesicles and is a well-characterized marker for autophagosome formation. 
LC3 is redistributed from the cytoplasm to the autophagosomes, which is associated with 
the conversion of LC3 from the LC3-I isoform to the LC3-II isoform (Lum et al. 2005a, 
Lum et al. 2005b). The conversion of LC3-I to LC3-II can also be measured via western 
immunoblotting.  
127 
The response to GRN163L does not induce rapid cell death via apoptosis or 
senescence (Chapter Three; Hochreiter et al. 2006), or decreased cell viability over the 
first two weeks (by three weeks, an increase of senescence and apoptosis can be seen 
with a significant decrease in the average telomere length). This does not, however, rule 
out the fact that loss of a sentinel, critically short telomere(s) may trigger alternate forms 
of growth arrest or cell death, such as autophagy as shown by the use of telomere-
targeting oligonucleotides (Aoki et al. 2007). As shown in Figure 5.1, there is preliminary 
evidence supporting the hypothesis of GRN163L-triggered autophagy by a decrease in 
the level of LC3-I and an associated increase in LC3-II over 72 hours after treatment with 
GRN163L.  
Mutations in the PTEN tumor suppressor gene as well as increased expression of 
PI3-kinase and Akt oncogenes are frequent events in human tumors. Interestingly, PTEN 
has been shown to have a role in inducing autophagy (Gozuacik and Kimchi 2004, Hait et 
al. 2006). Along with the increase in LC3-II, an increase in phosphorylated PTEN after 
treatment with GRN163L was observed (Figure 5.1). Taken together, the upregulation of 
LC3-II and PTEN suggest a potential induction of autophagy in response to GRN163L. 
However, PTEN has also been shown to have a role in FAK regulation as well, 
desphosphorylating FAK and inhibiting cell migration (Figure 5.2, Li et al. 2005). The 
upregulation of PTEN, therefore, could have multiple roles in the response to GRN163L. 
Although the basal level of FAK was measured, it is the phosphorylation pattern that 
regulates protein activity. It is possible that FAK phosphorylation is inhibited by 
GRN163L, resulting in the upregulation of a protein that has similar function in cell 
proliferation and migration.  
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Figure 5.1. GRN163L induces the conversion of LC3B-I to LC3B-II and the 
phosphorylation of PTEN. MDA-MB-231 cells were treated with 2.5 μM GRN163L or 
mismatch oligonucleotides for the depicted times. Western immunoblotting for the 
indicated adhesion and morphology proteins was performed. Densitometry levels were 
determined by comparing intensity of LC3B-I, LC3B-II, PTEN and phopsho-PTEN to 
GAPDH and relative intensity levels for each sample were plotted and normalized to 
untreated (UT) samples.  
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Figure 5.2. GRN163L disrupts cell structure and function. GRN163L has been shown 
to have an effect on cell adhesion, growth, migration, and proliferation. ├ = inhibition 
(direct or indirect).  The processes specifically investigated within this study are 
highlighted by an asterisk (*). Adapted from Li et al., Annu Rev Biomed Eng 2005. 
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As shown in Chapter Three, the reduction in breast cancer cell growth by 
GRN163L may be explained by the alterations in actin filament organization and 
decreased attachment to extracellular matrix ECM proteins, resulting in changes in 
proteins involved in maintaining cell shape, and regulating cell proliferation and 
migration. To support this hypothesis, antisense oligonucleotides have previously been 
reported to induce reversible, non-toxic effects on cells that are not related to protein 
inhibition. One of the more common events observed in response to antisense 
oligonucleotides is an inhibition of adhesion to the ECM, most likely due to interaction 
with membrane associated receptors (Figure 5.2). The structure of the oligonucleotides 
seems to play a role in this phenomenon, with oligonucleotides containing triplet-G and 
G-quartet sequences influencing cell morphology (Anselmet et al. 2002, Jackson et al. 
2007). The effects of GRN163L on cell adhesion and architecture is reversible with the 
addition of ECM proteins to cell culture dishes (Goldblatt et al. unpublished 
observations; Jackson et al. 2007). This reversibility indicates that GRN163L may be 
interfering with the ability of breast cancer cells to make or secrete ECM proteins, or the 
binding of integrins to the ECM (Figure 5.2). 
As an alternative mechanism underlying the response to GRN163L in cancer 
cells, based on the data derived from these studies, it is hypothesized that there is an 
induction of mitotic catastrophe. Mitotic catastrophe is cell death due to aberrant mitosis, 
often due to defective cell cycle checkpoints, DNA damage, abnormal spindle formation, 
and the subsequent generation of aneuploid cells (Eom et al. 2005, Castedo et al. 2004). 
This can often be due to premature mitosis prior to the completion of DNA replication 
and repair, or induced due to microtubule damage (Eom et al. 2005, Okada and Mak 
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2004, Bröker et al. 2005). Additionally, shortening of telomeric repeats beyond a 
critically short length leads to genomic instability and the formation of structural 
rearrangements, which can lead to the induction of mitotic catastrophe (Gisselsson 2005). 
There has been evidence that mitotic catastrophe can be induced by IR and chemotherapy 
(Gerwitz et al. 2008). Additionally, telomerase inhibition and subsequent telomere 
shortening has been shown to result in mitotic cell death, with evidence of senescing cells 
undergoing mitotic catastrophe (Gerwitz et al. 2008).  
The structural alterations induced by GRN163L (Chapter Three) characterized by 
disruption of actin filaments indicates that the response to GRN163L may, at least in part, 
be due to inability of cells to properly divide, further supporting the hypothesis that there 
may be an induction of mitotic catastrophe (Eom et al. 2005, Castedo et al. 2004). 
Telomere dysfunction induced by GRN163L could also lead to an induction of mitotic 
catastrophe (Chapter One), which would also help explain the reduction in growth rates 
seen in cancer cells in vitro, as well as tumor growth in vivo. To further support this idea, 
telomerase template mutations have been shown to block chromosome separation in 
anaphase (Kirk et al. 1997). Mutant hTR transfected into cells resulted in delayed 
doubling times, altered cell morphology, and cell death. These results indicate an 
important role for hTR in proper cell division (Kirk et al. 1997). In order to further 
understand the role of mitotic catastrophe in the response to GRN163L, the morphology 
of mitotic cells would be examined for abnormalities including multipolar anaphases, 
uneven chromosome distribution and cell cycle arrest. Additionally, the expression of 
genes that control mitosis can be measured via Western immunoblotting or real-time RT-
PCR techniques (Chang et al. 2000). 
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The relationship between telomerase and growth factor receptors in breast cancer 
is complex. The regulation of telomerase is not completely understood, although 
numerous reports have shown that telomerase can be upregulated through the MAPK 
pathway (Goueli et al. 2004, Maida et al. 2002, Ge et al. 2006). One published report 
demonstrated that HER2 amplification is associated with increased hTERT expression 
and telomerase activity (Goueli et al. 2004). Additionally, there is a link between 
telomerase activity and EGFR, with an upregulation of EGFR in telomerase-positive cells 
versus telomerase-negative cells. Furthermore, EGFR inhibition reduced the proliferative 
advantage of telomerase-positive cells (Smith et al. 2003). The activation of hTERT has 
been shown to be inhibited by MAPK pathway inhibitors, which supports the role of 
growth factor signaling in the induction of telomerase activity. Furthermore, targeting 
telomerase via siRNA and antisense oligonucleotides (AS-ODNs) in bladder cancer cells 
resulted in the down-regulation of EGFR (Kraemer et al. 2006). 
Ritter et al. showed that breast cancer cells selected for resistance to trastuzumab 
in vivo overexpressed epidermal growth factor receptor (EGFR) and phosphorylated 
EGFR. Furthermore, these cells remained dependent on ErbB receptor signaling and were 
sensitive to EGFR tyrosine kinase inhibitors, all of which may be regulated through 
insulin-like growth factor I (Ritter et al. 2007, Nahta et al. 2007a, Nahta et al. 2007b). 
Recent studies have demonstrated that HER2+ breast cancer cells have increased TGFβ 
signaling, resulting in increased survival and migration, as well as resistance to 
trastuzumab (Wang et al. 2008). As discussed in Chapter Four, GRN163L did not induce 
a change in the basal level of HER2 or EGFR activity (Figures 4.9-4.10 and data not 
shown). There was, however, a reduction in phosphorylated HER2 in the breast cancer 
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cell lines, indicating that GRN163L may be able to affect the expression and/or activity 
of growth factor receptors (Figure 5.2). This decrease in HER2 phosphorylation may 
underlie the synergistic effect of combination therapy with GRN163L and trastuzumab 
on HER2+ breast cancer cell growth. The involvement of major signaling pathways in 
trastuzumab-resistant cells indicates that the exact mechanisms of GRN163L effects on 
cell growth inhibition via the HER2/EGFR or IGF-I pathway may be complex and 
warrant further attention. Future implications of the work presented in Chapter Four 
include the design of clinical trials for GRN163L in combination with trastuzumab. 
 One concern with the use of telomerase inhibitors in the clinical setting is the 
potential effect on stem and progenitor cells found in highly replicative tissues, such as 
bone marrow, B and T cells, and gastrointestinal crypt cells. These cells, while largely 
quiescent, transiently express high levels of telomerase during proliferation (Chiu et al. 
1996, Broccoli et al. 1995, Counter et al. 1995, Hiyama et al. 2001, Bodnar et al. 1996, 
Hodes et al. 2002). They have also been found to have longer telomeres than most cancer 
cells. During the time that cells are quiescent, telomere shortening does not occur and 
telomerase activity is negligible (Chiu et al. 1996). It is therefore reasonable to expect 
that quiescent stem cells will not be significantly affected by short courses of telomerase 
inhibition therapy (Wright et al. 1996, Forsyth et al. 2002, Shay and Wright. 2002). 
Indeed, such effects have not been observed in either clinical trials or in preclinical 
toxicology studies of GRN163L. Importantly, Phase I trials have demonstrated that 
GRN163L is tolerated by patients with no dose-limiting toxicities or serious adverse side 
effects yet reported. More importantly, there has been a beneficial effect of treatment in 
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multiple patients with CLL, although results are still pending for the other clinical trials 
discussed in Chapter One.  
A major limitation of cancer immunotherapy in general is that for most cancers no 
foreign gene or protein is crucially involved in causing or maintaining tumor growth. The 
catalytic component of telomerase, hTERT, appears to be one such antigen due to near 
universal expression and crucial function in most tumors (Harley 2008). The use of anti-
telomerase immunotherapy is also being studied in non-small cell lung cancer, acute 
myeloid leukemia, chronic myeloid leukemia, gastrointestinal tumors, and central 
nervous system/brain tumors, pancreatic cancer, prostate cancer, and breast cancer. 
Clinical trials have revealed that patients treated with an hTERT vaccine have induced 
hTERT-specific cytotoxic T lymphocyte production without serious side effects 
(Vonderheide 2008, Brunsvig et al. 2006, Su et al. 2005, Vonderheide et al. 2004, 
Domchek et al. 2007). While there are many benefits to using anti-telomerase 
immunotherapy, there are also several drawbacks. Because many cancer cells have a low 
number of telomerase molecules, it is possible that tumor cells might present low levels 
of the hTERT epitope as well, which  might be a disadvantage for triggering killing by 
hTERT-specific immune cells. Additionally, many antigen presenting cells are primed ex 
vivo, introducing the risk of immune response against these cells. Furthermore, many 
patients have a weak immune system, thus hindering the effectiveness of vaccines 
(Harley 2008). Importantly for the continued use of telomerase vaccines, there have been 
no serious adverse side effects reported (Shay and Wright 2006). 
 Oncolytic viruses as gene therapy that utilize the hTERT promoter to drive 
expression of apoptosis genes have also shown potential to kill cancer cells (Shay and 
135 
Wright 2006, Gellert et al. 2005, Zimmerman and Martens 2007, Gu et al. 2000, Koga et 
al. 2000). This method of targeting telomerase-postive cells drives the expression of toxic 
genes, or “suicide genes” using the hTERT promoter to trigger cell death (Shay and 
Wright 2002, Shay and Wright 2006).  The expression of these suicide genes results in 
the rapid killing of telomerase-positive cells based on the increased expression of either 
hTR or TERT promoters in cancer versus normal cells. This method has limitations, 
however, with potential toxic effects of normal cells expressing the hTERT promoter. 
Additionally, effective delivery of gene therapy to cancer cells throughout the body is 
challenging, and vector systems have a propensity to induce immunological responses 
(Harley 2008, Shay and Wright 2002, Shay and Wright 2006). Additionally, gene therapy 
has been shown to result in “leaky” expression of the target gene, which could result in 
inappropriate expression of suicide genes in normal cells. 
 As discussed throughout this thesis, one potential problem with using telomerase 
in cancer therapy is the theoretically predicted lag time associated with effective 
treatment (Hahn et al. 1999, Zhang et al. 1999, Herbert et al. 1999, Kelland 2005, 
Zimmermann and Martens 2007, Saretzki 2003). While this means that telomerase 
inhibitors may not be used as solo therapy, there have been numerous reports that 
telomerase inhibition can sensitize cells to chemotherapy or irradiation (Masutomi et al. 
2005, Nakamura et al. 2005, Saretzki 2003, Kim et al. 2001, Goldkorn and Blackburn 
2006, Cerone et al. 2006a, Cerone et al. 2006b, Djojosubroto et al. 2005, Gomez-Millan 
et al. 2007, Ward and Autexier 2005). Furthermore, recent studies have shown that 
GRN163L has potent anti-metastatic potential in vivo (Dikmen et al. 2005, Hochreiter et 
al. 2006, Jackson et al. 2007). In addition to the known telomere dysfunction effects from 
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continuous telomerase inhibition, GRN163L has been shown to induce a rapid inhibitory 
effect on cell growth and invasion (Chapters Three and Four; Jackson et al. 2007). This 
rapid response to GRN163L synergistically inhibited the growth of breast cancer cells in 
vitro and in vivo with paclitaxel and trastuzumab, supporting the use of this compound in 
the clinical setting. 
 Two of the biggest problems associated with current therapeutic regimens are 
recurrence and the development of drug resistance in residual cells remaining after initial 
treatment. As discussed in this dissertation, GRN163L is readily taken up by cancer cells, 
inhibits telomerase activity, and reduces cell growth. Additionally, as discussed in 
Chapter Four, GRN163L is effective in drug resistant cells, and augments the effects of 
trastuzumab in these cells. One explanation underlying recurrence and drug resistance is 
the existence of cancer stem cells (CSC). Cancer stem cells are immortal, pluripotent 
cells with the capability for self-renewal and the capacity to give rise to multiple different 
lines of cancer cells (Shay and Wright 2006). As most therapeutics rely on rapid cell 
division, quiescent cancer stem cells are likely to be resistant to treatment have the ability 
to survive an initial tumor kill and generate tumor transit cells, which might allow the 
tumor to re-grow once the therapeutic regimen has ended (Smalley and Ashworth 2003). 
However, elimination of CSCs from a tumor could effectively eliminate recurrence. 
Importantly, CSCs have been reported to express telomerase activity, thus indicating the 
potential use of telomerase inhibition in targeting CSCs. The implications of this research 
demonstrating that GRN163L can sensitize drug-resistant cells can lead to future research 
into the effects of GRN163L on cancer stem cells.   
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 Based on the pre-clinical results from our laboratory, GRN163L entered Phase I/II 
trials for breast cancer in August 2008 in combination with paclitaxel and the anti-
angiogenic agent, bevacizumab (ClinicalTrials.gov Identifier: NCT00732056). The 
primary objectives of this study are to determine the maximum tolerated dose (MTD) of 
GRN163L in combination with paclitaxel/ bevacizumab in patients with locally recurrent 
or metastatic breast cancer, as well as the rate and duration of response to combination 
therapy. There are several known risks associated with phosphorothioate (PS) 
oligonucleotides that have been observed in certain pre-clinical studies evaluating the 
toxicity of GRN63L. These risks include prolonged clotting times, thrombocytopenia and 
anemia. All of these outcomes have been observed after treatment with GRN163L in the 
current clinical studies; however the effects of GRN163L are transient. In this clinical 
study, patients are treated with GRN163L and paclitaxel once weekly for three weeks, 
followed by one week of rest. The starting dose and schedule utilized in this study is 
based upon the results from the phase I single agent studies in patients with solid tumors 
and CLL.   
To measure the effectiveness of GRN163L in breast cancer patients, blood 
samples are being collected by our laboratory and analyzed for circulating tumor cells 
(CTCs). CTCs express telomerase activity, making them useful for screening and early 
cancer detection, but also for detection of residual disease after standard therapy (Mabruk 
and O'Flatharta 2005, Herbert et al. 2001, Soria et al. 1999). In addition, the level of 
telomerase activity in CTCs may have prognostic value, since cancers with high 
telomerase activity generally have poorer outcomes as compared to cancers with low 
telomerase levels. In addition, counting circulating tumor cells will determine whether 
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therapy with GRN163L is reducing the absolute number of CTCs or just inhibiting 
telomerase activity. However, cell death induced by standard therapeutics may decrease 
the number of CTCs and level of telomerase activity seen in blood samples, which could 
limit the knowledge of the exact contribution of GRN163L to standard therapeutic 
regimens. The telomerase activity assay described throughout this dissertation therefore 
has important applications as a prognostic tool (Herbert et al. 2006). 
In summary, a lipid-conjugated thio-phosphoramidate targeting the RNA template 
region of telomerase (GRN163L) is an effective telomerase inhibitor, and can synergize 
with radiation, paclitaxel, and trastuzumab therapy. These results further support the 
importance of telomerase in cell growth and survival and the dependency of cancer cells 
to telomerase. The findings presented in this thesis suggest several mechanisms 
underlying reduction in cell proliferation, tumor growth, and metastasis by GRN163L 
(Figure 5.3). The pathways underlying cell migration, death, and resistance to therapy are 
closely intertwined. GRN163L could be targeting multiple pathways in breast cancer cell 
growth and progression (Figure 5.2 and 5.3, pages 128-129). Importantly, there is an 
overarching theme for the mechanism underlying augmentation of the effect of all three 
forms of breast cancer therapy. Irradiation, paclitaxel, and trastuzumab treatment all 
invoke responses involving the DNA damage repair pathway, either through induction of 
irreparable damage, or through inhibition of damage repair (Bernier et al. 2004, Le et al. 
2005, Ramanathan et al. 2005). There is also a link between telomeres and DNA damage, 
as components of DNA damage response pathways have been found at the telomeres, and 
telomerase inhibition interferes with DNA repair (Nakamura et al. 2005, Gomez-Millan 
et al. 2007). Taken together with previous reports, the studies presented herein support 
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the use of telomerase inhibitors in combination with other therapeutic regimens for the 
treatment of breast cancer, metastasis, drug resistance, and recurrence. Treatment with 
telomerase template antagonists in therapeutic regimens could have beneficial outcome 
not only on primary tumor growth due to the effects of telomere shortening and 
dysfunction, but also in therapeutic regimens for sensitization to other forms of therapy. 
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Figure 5.3. Proposed mechanisms underlying response to GRN163L. The effects of 
GRN163L result in synergy with three types of breast cancer therapy through inhibition 
of multiple cellular functions. Telomerase inhibition is known to result in telomere 
dysfunction, reduced cell growth, and the induction of senescence or cell death. The 
research presented in this dissertation demonstrates that telomerase inhibition via 
GRN13L also results in inhibition of cellular adhesion, proliferation, structural 
maintenance, and migration.  
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